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Foreword
This white paper aims to launch a public debate on how the regulatory science in the field of nanotechnology-enabled health products can be further progressed (Box 1). The document 
summarizes and highlights the major regulatory needs that have been identified as a result of a 
number of communications with the regulatory community via questionnaires, workshops and bilateral 
discussions as well as a review of existing guidance, publications and other documents published by 
regulatory scientists. It also provides the context and underlying information related to challenges in 
regulating nanotechnology-enabled health products (Box 2).
Box 1. Definition of Regulatory Science (modified from the European Medicines Agency)
Regulatory science is defined as a range of scientific disciplines that are applied to the quality, safety 
and efficacy assessments of health products and that inform regulatory decision making throughout 
the lifecycle of a health product.
It encompasses basic and applied medicinal science and social sciences and contributes to the 
development of regulatory standards and tools.
Method developers, product inventors, academic groups, research funding organisations and 
regulators are considered as the major audience. The document intends to stimulate discussions 
related to necessary research activities within the community that can lead to scientific/technical 
solutions to address the challenges in regulating nanotechnology-enabled health products. Within the 
REFINE project, the presented analysis will provide guidance on the priorities to be addressed in the 
experimental work packages of the project. The annexes give an overview of the concerned regulatory 
and standardisation frameworks as well as on the involved key players, allowing the reader a better 
understanding of the context.
Box 2. Terms describing nanotechnology-enabled health products
A formal definition of nanomedicine does not exist and a variety of terms including nanomedicines, 
nanotechnology-enabled health products, nanotechnology-based products, products containing 
nano(bio)materials etc. are existing. For the purpose of this white paper the following terms are used:
“Nanomedicines”, describing products that are regulated as medicinal products
“Nanomedical devices”, describing products that are regulated as medical devices
“Nanotechnology-enabled health products” is an overarching term for both product classes.
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Executive Summary
The development of nanotechnology-based applications in the health sector offers innovative therapeutic and diagnostic opportunities to address medical needs. At the moment, no specific 
regulatory framework exists for nanotechnology-enabled health products but the current regulatory 
practice requires additional guidance in order to fully cover the particularities of such products. This 
white paper summarizes major challenges associated with regulating nanotechnology-enabled health 
products:
 ● Depending on their mode of action nanotechnology-enabled health products are regulated either 
as medicinal products or medical devices. However, due to the increased complexity of such 
products and their size-related properties, the selection of the regulatory path can become 
challenging since the primary mode of action might be difficult to determine. 
 ● Due to the fast progress in the field and the lack of robust datasets, only limited guidance 
on regulatory information needs is currently available and the question remains whether the 
identified requirements in this initial guidance are sufficient for a reliable characterisation and 
assessment of all nanotechnology-enabled health products. In order to generate the required 
information on the quality, safety and efficacy of the products, standardised testing methods 
have to be available. However, many conventional methods may not be suitable or reliable for 
nanomaterial testing, for example due to the interference of nanomaterial with assay components. 
On the other hand, new state-of-the-art methods, instruments, approaches or tools have not yet 
sufficiently proven their reliability and relevance for the given purpose.  
 ● As patents are expiring for certain nanomedicinal products, generic versions of the innovator 
products will require access to the market. Since the physicochemical characteristics can be very 
complex for nanotechnology-enabled products and achieved through sophisticated manufacturing 
processes, the current regulatory practice to assess the equivalence of the products may 
not be sufficient. More guidance is needed on how the similarity of follow-on products can 
be demonstrated and suitable standardised methods assessing the (bio) equivalence of such 
products need to be developed.
 ● The European definition of nanomaterials will apply for nanotechnology-enabled medical devices, 
outlining its classification and regulatory requirements. Yet, the implementation of the definition 
and the classification rule, introducing the need to define the internal exposure to nanomaterials, 
pose additional challenges.
The regulatory challenges highlighted in this white paper should guide the research projects and 
the involved communities willing to advance the regulatory science in the area of nanotechnology-
enabled health products. 
Box 3. REFINE consortium - Horizon 2020 project
Regulatory Science Framework for Nano(bio)material-based Medical Products and Devices
http://refine-nanomed.com/
Timeline: 1 December 2017- 30 November 2021
13 partners
Grant no 761104
Objectives:
• Identification of the most pressing regulatory and scientific challenges for 
nano(bio)material-based medicinal products and medical devices
• Development of a Decision Support System for the regulatory assessment of product
• Development and validation of new analytical or experimental methods
• Addressing harmonization needs
• Bridging involved communities and synergies across the sectors
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1 Introduction
Innovative nanotechnology-enabled health products are in the focus of an increasing number of research 
and development projects aiming to develop novel diagnostic and/or therapeutic concepts based 
on nanotechnology applications. However, such pioneering products can be very complex and might 
trigger regulatory concerns with regard to their quality and safety profile. In a communication to the 
European Parliament, the Council and the European Economic and Social Committee, the Commission 
confirmed already in 2008 that the Community legislative framework covers nanomaterials but the 
In addition, a number of possibilities exist that can support the approval process of nanomedicines, 
such as the scientific advice procedures of national competent authorities and of the European 
Medicines Agency (EMA), the EU-Innovation Network (since 2015) and EMA’s Innovation Task Force 
(ITF) (EMA, 2014). This task force brings together scientific and regulatory expertise to provide support 
on emerging therapeutic areas such as gene and cell therapy, regenerative and personalised medicines, 
pharmacogenomics, nanotechnology applied to medicines, biomarkers, and novel statistical models. 
In collaboration with regulatory authorities from US, Japan, Canada and Australia, the Committee 
for Medicinal Products for Human Use (CHMP) organised an expert meeting addressing specifically 
the development of nanomedicines. In 2010 EMA organised the 1st International Workshop on 
Nanomedicines aiming to share competencies and facilitate dialogue between regulators, academia, 
industry and patients (Figure 1). 
Since then the CHMP Drafting Group on Nanomedicines released a number of Reflection Papers (EMA/
CHMP, 2013a, 2013c, 2013b, 2015) related to different categories of nanotechnology based products. 
The Working Group on Nanomedicines of the International Pharmaceutical Regulators Programme 
2009
Ad Hoc CHMP Expert 
Group meeting on 
Nanomedicines
2010
1st International 
Workshop on 
Nanomedicine (EMA)
2013
Release of Reflection 
Papers for nanomedicines 
(CHMP, EMA)
2015
Release of Reflection 
Papers for nanomedicines 
(CHMP, EMA)
2016
Global Summit on 
Regulatory Science (GSRS) 
workshops 
2017
"Bridging communities in the field of 
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2008
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Key reference:
GSRS (2016). Nanotechnology Standards and 
Applications. Report. 
https://www.astm.org/COMMIT/GSRS16 Final Report.pdf
Nanotechnology-enabled 
health products follow 
current regulatory 
frameworks for medicinal 
products or medical 
devices.
Figure 1: Milestones advancing the development of 
a regulatory framework for nanotechnology-enabled 
health products 
Key reference:
EC (2008). Communication from the Commission to 
the European Parliament, the Council and the European 
Economic and Social Committee- Regulatory aspects 
of Nanomaterials [SEC(2008) 2036] 
implementation of the legislation requires further elaborations e.g. when it comes to test methods 
and risk assessment methodologies. 
For products such as medicinal products or medical devices that are subject to a pre-market control 
or pre-market notification, the assessment and management of risks in relation to nanomaterials are 
verified by competent authorities or Notified Bodies before placing them on the market (EC, 2008). 
(IPRP) discusses in biannual meetings upcoming regulatory challenges related to products containing 
materials in nanoscale. 
The Global Coalition for Regulatory Science Research organised the Global Summit on Regulatory 
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Science (GSRS) workshops in 2015 and 2016 dedicated to nanotechnology. In particular, participants of 
the workshop in 2016 identified the main standardisation needs including needs for nanotechnology-
based biomedical applications (GSRS, 2016) which will be further updated in the GSRS 2019 on 
nanotechnology and nanoplastics. 
In 2017, the EC Joint Research Centre organised a workshop on “Bridging communities in the field 
of nanomedicine” which gathered experts from research institutions, industry and regulatory bodies 
(Halamoda-Kenzaoui et al., 2019). The workshop resulted in a set of recommendations emphasising 
needs in immunological assessment of nanomedicines, quality attributes and standardisation. The 
recommendations of the experts were in particular relevant for the H2020 REFINE project which aims 
to advance the regulatory science in the field of nanomedicine.
For medical devices, the European Commission’s Working Group on New and Emerging Technologies 
first flagged the need for special attention for nanotechnology-enabled medical devices in 2007. Since 
then, this working group has regularly provided input for regulatory (scientific) aspects related to this 
topic, especially during the development and implementation of the recently published new Medical 
Device Regulations. In 2015, the Scientific Committee for Emerging and Newly Identified Health Risks 
(SCENIHR) adopted their Guidance on the Determination of Potential Health Effects of Nanomaterials 
Used in Medical Devices (SCENIHR, 2015). Furthermore, in 2017 ISO published the ISO/TR 10993-22 
Biological evaluation of medical devices, Part 22 Guidance on nanomaterials (ISO/TC 194, 2012).
The identified regulatory challenges, summarised in this report, now require a wider debate in the 
community on how the recognised challenges can be addressed. Tailor-made research strategies 
for the various product classes are necessary in order to fill identified knowledge gaps. In addition, 
necessary background information on the principles of the current regulatory frameworks of medicinal 
products and medical devices and a short description of the major players in the regulation of 
nanotechnology-enabled health products will support the reader in getting an overview on the highly 
complex regulatory frameworks at European and international level (see Annexes). 
2 Regulatory and scientific 
challenges
2.1 Identification of regulatory information 
needs for nanotechnology-enabled 
products
Nanotechnology-enabled health products are regulated under the existing regulatory frameworks of 
medicinal products and medical devices but may require additional quality and safety assessments 
triggered by the unique characteristics of the nanomaterial. The identification and a general agreement 
on the regulatory requirements relevant for the assessment of a product is therefore a pre-requisite 
for a smooth approval process of a medicinal product or a medical device containing nanomaterial. 
Currently only limited guidance is available (Table 1) since robust datasets allowing a firm conclusion 
on information requirements needed for regulatory decisions are lacking. In addition, the increasing 
complexity and the huge variety of the next generation of nanomedicines and nanomedical devices 
(see Annex C) might even require more specific guidance.
This situation is leading to a high uncertainty for product developers and the lack of such guidance 
to prove compliance with the regulatory requirements may hamper the development and marketing 
of nanotechnology-enabled products. At the same time high quality data on safety, efficacy and 
quality for innovative products necessary for a better definition of regulatory requirements will not 
be generated (Figure 2). This vicious circle can only be broken in an iterative process that leads to the 
identification of physicochemical properties with clinical relevance. 
Challenge 1:
Is the existing guidance sufficient for regulating the next 
generation of nano-enabled health products? 
The identification and linkage of quality attributes to the safety 
and efficacy of the product is an important aspect within the 
quality-by-design approach (Bastogne, 2017).
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Table 1: Regulatory documents specifically addressing nanotechnology-enabled health products*
 
 
9 
 
 
Category of product addressed by 
the document 
Initial guidance documents addressing nanotechnology-based medical products 
All products including health care products 
Consumer products including 
medical products 
 SCENIHR. Risk assessment of products of nanotechnologies; 2009 
 
Products containing nano-silver  SCENIHR. Nanosilver: safety, health and environmental effects and role in 
antimicrobial resistance; 2014 
Medicinal products 
Medicinal products containing 
nanomaterials 
 EMA Reflection paper on nanotechnology-based medicinal products for Human Use. 
EMEA/CHMP/79769/2006 
 FDA/CDER. Guidance for Industry: Drug Products, including Biological Products, that 
Contain Nanomaterials: (2017) (draft guidance) 
Liposomal products 
 EMA/CHMP. Reflection paper on the data requirements for intravenous liposomal 
products developed with reference to an innovator liposomal product. London; 2013; 
EMA/CHMP/806058/2009/Rev.02. 
 FDA/CDER. Guidance for Industry. Liposome Drug Products 
Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; 
and Labeling Documentation (2018) 
 MHLW. Guideline for the development of liposome drug products (2016) 
Block copolymer micelle products  EMA/CHMP/ MHLW. Joint MHLW/EMA reflection paper on the development of block 
copolymer micelle medicinal products. London; 2013; EMA/CHMP/13099/2013. 
Iron based nano-colloidal 
products 
 EMA/CHMP. Reflection paper on the data requirements for intravenous iron-based 
nano-colloidal products developed with reference to an innovator medicinal product. 
London; 2015; EMA/CHMP/SWP/620008/2012. 
Nucleic acid-loaded 
nanotechnology based drug 
products 
 MHLW. Reflection paper on nucleic acids (siRNA)-loaded nanotechnology based drug 
products (2016) 
Coated nanomedicine products 
 EMA/CHMP. Reflection paper on surface coatings  : general issues for consideration 
regarding parenteral administration of coated nanomedicine products. London; 2013; 
EMA/325027/2013. 
Medical devices 
Medical devices containing 
nanomaterial 
 SCENIHR. Opinion on the guidance on the Determination of Potential Health Effects of 
Nanomaterials Used in Medical Devices; 2015 
 ISO TR 10993-22: Biological Evaluation of medical devices – Part 22: Guidance on 
nanomaterials. 
 
EMA: European Medicines Agency, FDA: Food and Drug Administration (USA), MHLW: Ministry of Health, Labour and Welfare (Japan), SCENIHR: Scientific 
Committee on Emerging and Newly Identified Health Risks. 
*EMA: European Medicines Agency, FDA: Food and Drug Administration (USA), MHLW: Ministry of Health, Labour and 
Welfare (Japan), SCENIHR: Scientific Committee on Emerging and Newly Identified Health Risks.
1. REGULATORS 
Limited experience with 
regulating innovative 
nanomedicines
2. REGULATORS
Provide only initial guidance
3. PRODUCT DEVELOPERS
Uncertain data requirements
for product developer
4. PRODUCT DEVELOPERS
Heterogeneous/ insufficient datasets available for safety 
and quality assessments of nanomedicines
6. REGULATORS
Delay in harmonising 
regulatory practice
5.REGULATORS
Lack of robust datasets
Figure 2: The vicious circle showing interdependence of availability of regulatory guidance and the generation of data 
related to the characterisation of nanomedicines
In order to get an overview on the current status of the regulatory requirements, the characterisation 
needs addressed in currently available regulatory documents (Table 1) were extracted and categorised 
(Table 2). Such exercise may help to identify standardisation needs, raise regulatory awareness 
on safety concerns reported in the scientific literature and recognise harmonisation opportunities 
between the regions.
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Table 2: Quality and nonclinical information needs relevant for all categories of nanotechnology-based medical products. 
Physicochemical parameters 
(if applicable) 
Biological characterisation 
 Detailed description of all components 
 Chemical composition 
 Chemical structure 
 Structural attributes that relate to function (e.g., lamellarity, 
core-shell structure 
 Crystal form  
 Impurities 
 Particle size and size distribution 
 Shape and morphology 
 Surface properties (e.g., surface area, surface charge, chemical 
reactivity, ligands, hydrophobicity, and roughness); 
 Particle concentration 
 Porosity (if it relates to a function) 
 Degradation path, kinetics and degradation products 
 Stability, both physical and chemical 
 In-use stability studies at clinically relevant concentrations and 
under relevant storage conditions 
Drug delivery systems 
 Drug loading efficiency 
 Assay and distribution of any active ingredient associated with 
the nanomaterial and free in solution (e.g., surface bound or 
liposome encapsulated versus free active ingredient) 
 Physical state of the active substance 
 In vitro drug substance /siRNA release rate in 
physiologically/clinically relevant media 
Bioburden control 
 Sterility and endotoxin levels 
Pharmacokinetic parameters 
 Stability in blood and serum 
 Biological fate 
 Accumulation issues 
 ADME 
 Plasma Protein Binding (formation of PC over time) 
 In vivo degradation/solubilisation rate and place of 
degradation 
Pharmacodynamical parameters 
 Biocompatibility with blood and serum 
 Additional risks associated with the exposure route:  
topical application: skin penetration, distribution in lymph 
nodes, subcutaneous administration: sensitisation to 
allergens, inhalation: effect on the respiratory system, iv: 
hemocompatibility 
 In vitro uptake and cytotoxicity of nanomaterials to the 
phagocytes 
 Interaction with enzymes e.g. Cytochrome P450 
 Immunogenicity (ICH S8) 
 Complement activation 
 
based on FDA and EMA regulatory guidance (EMA/CHMP, 2006; FDA, 2017)  or included in at least three different guidance documents addressing specific 
categories of nanomedicines; ADME: Absorption/distribution/metabolism/elimination profile, PC: protein corona 
 
 
 
Table 2: Quality and nonclinical information needs relevant for all categories of nanotechnology-based medical products the contamination of nanoparticulate products with the endotoxin is a frequently encountered issue, 
requiring specifically adapted detection methods. Interestingly, binding of the plasma protein and the 
formation of the protein corona should be investigated for nanoparticle-based products that will enter 
the blood circulation. Identification of the major proteins that will bind to NP surface and the amount 
of proteins that will bind over time can give some insights into the circulation time, biodistribution and 
risk of the immunological effects. Immunotoxicity is not automatically tested for all medicinal products 
but may be triggered as a result of standard toxicity studies if showing alterations in routinely tested 
parameters that may indicate the risk of adverse immune effects. 
However, these studies, performed in animal models, may not always be predictive for effects in 
humans, due to inter-species variability of the immune system, and may not always detect more subtle 
immune reactions induced frequently by nanomaterials (Giannakou, Park, et al., 2016; Halamoda-
Kenzaoui & Bremer-Hoffmann, 2018). 
Therefore the evaluation of potential immunogenicity issues was addressed in several documents 
addressing nanotechnology-enabled products requiring suitable methods to provide the requested 
information. 
In addition to the already identified characterisation requirements, there is a need to monitor the 
information that becomes available through research activities or (pre)clinical studies pointing to any 
kind of safety concern that require regulatory awareness. 
Additional understandings on the correlation of physicochemical 
properties and the biological effects of products require 
particular attention.
In frame of REFINE an attempt will be made to screen the scientific literature using advanced tools in 
order to identify eventual safety issues of nanotechnology-based products, that are not covered yet 
in the existing regulatory guidance (Table 1).
2.1.1 Example of regulatory and scientific issues: 
Pharmacokinetics of nanotechnology-enabled 
medicinal products
Nanomedicines to date have demonstrated an enhanced bioavailability, efficient penetration into the 
lymphatic system, persistence in the circulation, increased binding capacity to biomolecules and an 
improved penetration into target tissues. These effects are a result of significant differences in the 
absorption, distribution, metabolism and elimination (ADME) profiles of nanomaterials in comparison 
The characterisation needs addressed in regulatory documents (Table 2) are not claimed to 
be compulsory information to provide by product developers but should rather be considered as 
suggested endpoints for quality and safety assessments. In addition, the specific guidance for 
nanotechnology-enabled products should be seen in connection with the applicable ICH guidelines or 
CEN/ISO standards, for medicinal products and medical devices, respectively. 
Among the extracted physicochemical parameters, a major part refers to the nanoscale properties 
specific for or associated with the materials under investigation. Some of these are size, shape, 
morphology, chemical structure and structural attributes, surface properties and coating description. 
Others, refer to standard regulatory requirements for medicinal products, but were specifically 
addressed in the guidance documents to emphasize the risk of potential concerns when dealing with 
nanomaterials. For instance, stability, although required for all medicinal products, can be particularly 
complex to assess in case of nanomaterials, as several physical and chemical processes need to be 
considered (e.g. aggregation and agglomeration or separation, degradation, drug leakage or release 
etc.). Sterility and endotoxin levels are specifically mentioned in the FDA guidance (FDA, 2017), since 
Key reference:
Giannakou et al (2016). A comparison of immunotoxic 
effects of nanomedicinal products with regulatory 
immunotoxicity testing requirements. Int. J. 
Nanomedicine 11, 2935–2952. 
to small-molecule counterparts. Several nano-
formulations have been developed for the 
purpose of increasing efficacy and reducing 
adverse events by altering the pharmacokinetic 
properties of an already licensed drug. In 
particular, increased oral bioavailability 
or prolonged terminal half-life for orally 
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administered nanomedicines have been successful in reducing dosage, frequency of administration 
and toxicity (Irby, Du, & Li, 2017; Maranhão, Vital, Tavoni, & Graziani, 2017). Efforts to develop 
these characteristics are likely to provide novel platforms for the treatment of specific diseases that 
have previously been a challenge using conventional small-molecule drugs. In particular, they will 
provide tools for the implementation of personalised medicine (Theek, Rizzo, Ehling, Kiessling, & 
Lammers, 2014) and will be instrumental for treating orphan diseases. However, the differences 
in pharmacokinetics or distribution can give way to persistent and elevated drug concentrations in 
plasma or tissues and may present additional safety concerns related to nano-specific effects (Wu & 
Tang, 2018). 
European guidelines for the preclinical and clinical assessment of pharmacokinetics for medicinal 
products have been developed before nanomedicines became more common. An expanded dataset 
might be needed to address the specificities of the pharmacokinetic profiles of nanomedicines. As 
the medical applications of nanotechnology utilise innovations from multiple disciplines, this requires 
cross-citation between regulatory guidance documents developed for different sectors. There has 
been some uncertainty on the robustness of preclinical datasets necessary to provide adequate 
pharmacokinetic information for regulatory approval from different bodies.
Also, the current Food and Drug Administration (FDA) final guidance documents, other than those 
that are product-specific, do not provide a comprehensive review of what is required in terms of the 
pharmacokinetic evaluation of nanomedicines. However, the recently released draft set of guidelines 
provide some nano-specific considerations for ADME. This document takes into consideration 
the potentially harmful clinical adverse events, such as accumulation in off-target sites that are 
not necessary to consider for small-molecule compounds. A panel of preclinical pharmacokinetic 
assessments for the delineation of safety and toxicity depending on their route of administration is 
presented that may aid nanomedicine researchers in structuring their preclinical evaluation of these 
compounds to accelerate submission (FDA, 2017). 
2.2 The selection of the regulatory framework
The unique opportunities of nanomaterials used in health products might lead to challenges when it 
comes to the selection of the regulatory path. The classification of a product into a medicinal product 
or a medical device depends on the primary mode of action (Box 4) but the decision is not always 
easy.
Such products are called borderline products and require special attention by the regulatory community. 
Since the regulatory pathways for market authorization of medicinal products versus medical devices 
are substantially different, it is very important for product developer to get into contact with the 
regulatory authority as early as possible. Regulatory agencies have set up several mechanisms that 
provide scientific advice and support innovation in health care e.g. EMA’s Innovation Task Force, the 
1EMA PRIME: Priority medicines: https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines
Challenge 2:
Can we always clearly define the primary mode of action 
of nano-enabled health products? 
scientific advice procedure offered by EMA and 
the national competent authorities as well as 
EMA’s PRIME scheme for priority medicines 
targeting unmet medical needs1. A Borderline 
and Classification Expert Group is established 
and coordinated by the European Commission in 
order to discuss and assist in the classification 
of the borderline products.
Current research activities focus on the 
development of multifunctional drug delivery 
systems that release their therapeutic cargo 
to the diseased tissue and act through external 
stimuli such as magnetic fields, ultrasound, 
pH, temperature, light etc. (Figure 3). Such 
hybrid structures combining physical stimuli 
with pharmacologically active substances pose 
additional challenges in their regulation, since 
they can exhibit more than one mechanism of 
action. Depending on their main mode of action 
they have to follow primarily the regulatory 
framework of medicinal products or medical 
devices, while the component with the ancillary 
action has to comply with the other framework. 
Box 4. Regulatory definitions
Medicinal Products Medical Devices
(a) Any substance or combination 
of substances presented as 
having properties for treating 
or preventing disease in human 
beings; or
(b) Any substance or combination 
of substances which may be used 
in or administered to human 
beings either with a view to 
restoring, correcting or modifying 
physiological functions by exerting 
a pharmacological, immunological 
or metabolic action, or to making 
a medical diagnosis.
(Directive 2001/83/EC)
any instrument, apparatus, appliance, software, 
implant, reagent, material or other article 
intended by the manufacturer to be used, alone 
or in combination, for human beings for one or 
more of the following specific medical purposes:
 — diagnosis, prevention, monitoring, prediction, 
prognosis, treatment or alleviation of disease, 
— diagnosis, monitoring, treatment, alleviation 
of, or compensation for, an injury or disability, 
— investigation, replacement or modification of 
the anatomy or of a physiological or pathological 
process or state, — providing information by 
means of in vitro examination of specimens 
derived from the human body, including organ, 
blood and tissue donations,
 and which does not achieve its principal intended 
action by pharmacological, immunological or 
metabolic means, in or on the human body, but 
which may be assisted in its function by such 
means. The following products shall also be 
deemed to be medical devices: — devices for 
the control or support of conception; — products 
specifically intended for the cleaning, disinfection 
or sterilisation of devices as referred to in 
Article 1(4) and of those referred to in the first 
paragraph of this point.
(Medical Device Regulation (EU) 2017/745)
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In addition, the increasingly overserved convergence of nanotechnology with other key enabling 
technologies is leading to highly innovative products combining e.g. a medicinal product with a device. 
Such combination products can pose now additional challenges in their governance. Depending on 
their primary mode of action they have to be compliant with the regulatory frameworks of medicinal 
products or medical devices. Recently, EMA has released a draft guideline on the quality requirements 
for drug-device combinations providing more information on such complex products (EMA, 2019).
shell
core
active principle
stealthing
imaging
agent
targeting moietiesY
Temperature
pH
Magnetic ﬁeld
Enzyme
Redox
Light
2.3 The European definition of nanomaterial 
and its implication for nanotechnology-
enabled health products
Box 5. Nanomaterial and other related definitions in the medical device regulation (EU 2017/745)
Challenge 3:
How to implement classification rule 19 and the EC 
definition of nanomaterial as used in medical devices 
regulation?
Figure 3: Theoretical example of a borderline product
Hybrid structure combining physical stimuli with pharmacologically active substances require special attention and 
may need the navigation between several directives and frameworks
The components of the product may belong to several 
categories including biopharmaceuticals, advanced therapy 
medicinal products and medical devices, which requires the 
navigation between several directives and frameworks.
Key reference:
EU (2011). Commission Reccomendation of 18 October 
2011 on the definition of nanomaterial.
Off. J. Eur. Union L275, 338–40.
In 2011 the European Commission published a recommendation on the definition of a nanomaterial, 
which is not mandatory, however Member States, the EC agencies and economic operators are invited 
to use it (EU, 2011). 
Whereas the recommendation has no implications for nanomedicines since the EMA has developed its 
own working definition, the medical device regulation has almost entirely adopted the EU definition of 
nanomaterials (Box 5) with two differences: 
1. the definition in the medical device regulation does not contain the possibility to adjust the 50% 
number size distribution threshold for specific cases 
2. nanomaterials cannot be identified via the specific surface area.
(18) ‘nanomaterial’ means a natural, incidental 
or manufactured material containing particles 
in an unbound state or as an aggregate or as 
an agglomerate and where, for 50 % or more 
of the particles in the number size distribution, 
one or more external dimensions is in the size 
range 1-100 nm; 
Fullerenes, graphene flakes and single-wall 
carbon nanotubes with one or more external 
dimensions below 1 nm shall also be deemed 
to be nanomaterials; 
(19) ‘particle’, for the purposes of the definition 
of nanomaterial in point (18), means a 
minute piece of matter with defined physical 
boundaries; 
(20) ‘agglomerate’, for the purposes of the 
definition of nanomaterial in point (18), means 
a collection of weakly bound particles or 
aggregates where the resulting external surface 
area is similar to the sum of the surface areas 
of the individual components; 
(21) ‘aggregate’, for the purposes of the 
definition of nanomaterial in point (18), means 
a particle comprising of strongly bound or fused 
particles;
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Challenge 4:
Is the existing regulatory framework for assessing the 
equivalence of generic products sufficient for follow-
on nanomedicinal products? 
2.4 Challenges in assessment of follow-on 
products (“nanosimilars”)
Since patents protecting some of the first marketed nanomedicines have expired or are close to 
expiry, new opportunities for the development of generic nanomedicines also known as “follow-on 
nanomedicines” or “nanosimilars” occur. The term “nanosimilars” has been derived from the term 
“biosimilars” which faced comparable challenges to demonstrate their similarity and bioequivalence 
to the innovator products. Currently no specific regulatory pathway is designed for nanosimilars and 
the level of comparability with the innovator product has to be demonstrated following the legislative/
regulatory path of generic products. The legislation states in its Article 10 (1) of Directive 2001/83/
EC: … the applicant is not required to provide the results of preclinical tests and clinical trials if he 
can demonstrate that the medicinal product is a generic medicinal product of a reference medicinal 
In order to support product developers the EMA has released a Reflection Paper (RP) for liposomal 
formulations which also includes indications on regulatory needs for nanosimilars. The RP concluded 
that differences in liposome characteristics might not be detectable by conventional bioequivalence 
testing alone, and additional studies are needed. A regulatory approach similar to the one established 
for similar biological medicinal products (biosimilars) that requires the stepwise comparability 
approach for quality, safety and efficacy between the reference product and the biosimilar was 
considered, highlighting that differences between the product claimed to be similar (follow-on) and the 
However, there is an ongoing confusion how to interpret the various terms used in the EC definition as 
well as in the medical device regulation, in particular in combination with classification rule 19 which 
is referring to medical devices containing nanomaterial. 
In addition, technical and scientific discussions on how to measure the different parameters mentioned 
in the legislative texts are still ongoing. An overview of concepts and terms, which might help solve 
the confusion, has recently been published (Rauscher et al., 2019).
studies or whether a more detailed and more expensive clinical trial is needed, including a full set of 
clinical efficacy and/or safety studies (Mühlebach, Borchard, & Yildiz, 2015). 
This recommendation is driven by observations that apparently similar structures, with similar 
PK profiles have shown different safety and efficacy outcomes. The establishment of therapeutic 
equivalence, based on the existing methods and tools, is challenging. 
Clinically significant quality attributes need to be identified 
with a known and understood influence on disposition, safety 
and/or efficacy of the product. 
Such knowledge is decisive to define the need for additional clinical research, and the design of clinical 
trials. If molecular and functional similarities are not fully demonstrated, reduced requirements for 
clinical studies cannot be implemented. This may imply the need for Phase I-IIA clinical trials, including 
healthy volunteers (safety) but also patients (efficacy).
Some examples demonstrating the regulatory challenge already exist: an application for a generic 
version (Lipodox) of Caelyx was not accepted by the EMA. The assessment report pointed out that 
“there are outstanding major nonclinical and clinical objections which preclude a recommendation 
Key reference:
Rauscher et al (2019). An overview of concepts and 
terms used in the European Commission’s definition of 
nanomaterial. JRC Sci. Policy Rep. EUR 29647.
Key reference:
Mühlebach et al (2015). Regulatory challenges and 
approaches to characterize nanomedicines and their 
follow-on similars. Nanomedicine 10, 659–674. 
product which is or has been authorized under Article 6 of Directive 2001/83/EC for not less than 8 
years in a Member State or in the Union... (EC, 2001)
A generic medicinal product is defined as a medicinal product that has:
• the same qualitative and quantitative composition in active substance(s) as the reference 
product,
• the same pharmaceutical form as the reference medicinal product,
• and whose bioequivalence with the reference medicinal product has been demonstrated by 
appropriate bioavailability studies.(EC, 2001)
authorised reference medicinal product with regard to manufacturing process steps and formulation 
may substantially modify efficacy/safety. The design of clinical studies is crucial for nanosimilars.
A better understanding is necessary whether clinical trials can be limited to pharmacokinetics (PK) 
for marketing authorisation at the present time". However, the compound was accepted as generic 
version of Doxil by the US FDA.
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2.5 Methods addressing regulatory 
information needs Challenge 5:
Can existing standards provide the information needed 
for regulatory decision making?Appropriate characterization as well as the assessment of quality, safety and efficacy of nanotechnology-enabled health products requires the availability of reliable methods that can address identified 
regulatory needs. Due to the specific properties of the materials at the nano-scale level, not all 
conventional testing methods might provide reliable results (Box 6).
A recent review (Halamoda-Kenzaoui et al., 2018) provided an overview on the existing standardised 
methods in the nanotechnology area that could be of relevance for nanotechnology-enabled health 
products.
For the characterisation of nanoscale-specific physicochemical parameters such as particle size, 
shape, surface charge, several methods were developed and standardised by the ISO Technical 
Committee on Nanotechnologies. In addition, other standardised methods, mainly from the material 
science area, might be suitable to measure additional chemical and physical parameters. However, 
some particular functionalities of nanotechnology-enabled delivery systems such as drug loading, 
drug release from the carrier, surface functionalisation or targeting capabilities need very specific, 
sophisticated methods, that are still under development. In addition, depending on the material 
properties, dispersion characteristics and method principles, the applicability of methods to a given 
nanomaterial can vary. Choosing inadequate methods can lead to unprecise or unreliable results 
requiring regulatory attention.
Another aspect is the interaction of medical products with biological fluids, where the presence of 
proteins and biomolecules can strongly impact the stability of dispersions and provoke immunological 
reactions. Therefore, the characterisation should ideally be performed not only in pristine state, but 
also in a biological medium of relevance.
Several challenges persist also regarding the toxicological evaluation of nanomaterials. Due to their 
specific physicochemical characteristics such as optical properties they can interfere with biological 
assays and their detection systems, e.g. increasing/decreasing the optical density or adsorbing proteins 
on their surface (Guadagnini et al., 2015). 
In addition, particle contamination with bacterial endotoxin is very challenging to measure and can 
highly impact results of toxicological studies (Giannakou, Geertsma, et al., 2016). Therefore, existing 
methods should be reviewed for their suitability to test nanomaterials and, where necessary, suitable, 
adapted for nanomaterials, methods need to be developed (Giannakou et al., 2019).
Currently, only a few in vitro standardised methods are specifically developed for nanotechnology-
enabled health products (Table 3). 
Most of them were published by ASTM International Committee E56 on Nanotechnology (see 
Annex A.10). However, ASTM standards are not legally binding in the European frameworks for 
nanotechnology-enabled health products.
Guidance related to the biological evaluation of medical devices, containing nanomaterials has 
been released in 2017 by ISO, as a part of ISO/TR 10993 multi-part guidance. Additional in vitro 
Key reference:
Halamoda-Kenzaoui et al (2018). Mapping of the 
available standards against the regulatory needs 
for nanomedicines. Wiley Interdiscip. Rev. Nanomed. 
Nanobiotechnol. e1531. 
Table 3: Overview on available standardized methods and guidance addressing biological evaluation of nanotechnology-
enabled medical applications
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Table 3: Overview on available standardized methods and guidance addressing biological evaluation of nanotechnology-enabled medical 
applications. 
Test method/guidance Endpoint Reference Comments 
Biological evaluation of medical devices- Part 
22 Guidance on nanomaterials 
Physicochemical and 
biological evaluation 
ISO/TR 10993-
22:2017 
Intended for medical devices; 
probably partly useful for 
medicinal products as well 
Determination of silver nanoparticles potency 
by release of muramic acid from 
Staphylococcus aureus 
Antimicrobial efficacy ISO/TS 16550:2014 
Not only medicinal products 
but also textile products, 
other consumer products 
Standard Test Method for Analysis of Hemolytic 
Properties of Nanoparticles 
Biocompatibility, 
hemolytic properties 
ASTM E2524 - 
08(2013) 
Similar to Practice F756 but 
modified to accommodate 
nanoparticulate materials 
Standard Test Method for Evaluation of 
Cytotoxicity of Nanoparticulate Materials in 
Porcine Kidney Cells and Human 
Hepatocarcinoma Cells 
Cytotoxicity 
assessment using MTT 
and LDH assays 
ASTM E2526 - 
08(2013) 
 
Standard Test Method for Evaluation of the 
Effect of Nanoparticulate Materials on the 
Formation of Mouse Granulocyte-Macrophage 
Colonies 
Immunological 
response 
ASTM E2525 - 
08(2013) 
 
Several characterisation methods suitable for nanomedicinal product assessments have been developed by laboratories such 
as the NCI-NCL2  and the EUNCL3. A large fraction of these protocols is probably also relevant for the assessment of 
nanomaterials released from medical devices. Such expert laboratories support the translation of nanotechnology-enabled 
applications providing technical know-how and scientific expertise necessary for a detailed physicochemical characterisation, 
as well as in vitro and in vivo safety testing of candidate products. In addition to providing the services of the characterization 
                                                             
 
2 Nanotechnology Characterization Laboratory (NCI-NCL): https://nanolab.cancer.gov/ 
3 European Nanomedicine Characterisation Laboratory (EUNCL): http://www.euncl.eu/ 
Box 6. Methodological challenges:
Limited reliability for heterogeneous materials
Material dependent applicability
Measurements in biological environment
Nanomaterial interference with assay components
24 25
2.6 Terminology
A harmonised terminology and established definitions are 
essential in any field of science and technology for a mutual 
understanding among different communities of stakeholders 
including scientific experts and regulators. 
An emerging technology, such as nanomedicine, is usually stimulating the generation of new terms, 
concepts and definitions, which may be used ambiguously by various stakeholders having diverse 
interests and coming from different backgrounds. 
toxicological test methods for nanomaterials were published by ISO (Halamoda-Kenzaoui et al., 
2018). Nevertheless, their applicability to health products is not fully understood.
Several characterisation methods suitable for nanomedicinal product assessments have been 
developed by laboratories such as the NCI-NCL2 and the EUNCL3. A large fraction of these protocols 
is probably also relevant for the assessment of nanomaterials released from medical devices. Such 
expert laboratories support the translation of nanotechnology-enabled applications providing technical 
know-how and scientific expertise necessary for a detailed physicochemical characterisation, as well 
as in vitro and in vivo safety testing of candidate products. In addition to providing the services of 
the characterization of nanomedicines, they actively develop and optimise protocols relevant for 
nanomedicinal product assessments. As such those protocols provide a good starting point for the 
standardisation of methods (see Annex B4).
Finally, one of the main REFINE’s objectives is to develop and standardise those methods that are 
relevant for the regulatory assessment of nanotechnology-enabled health products. For this reason 
current regulatory requirements will be identified and available methods will be compiled allowing 
gap analysis. REFINE will focus on methods for the immunotoxicity assessment having potential to 
detect adverse effects of nanomedicines early in the preclinical stage.
The development of new methods claiming to characterise reliably nanomaterial is constantly 
increasing. However, an independent verification of the reliability and relevance of such methods 
for regulatory purposes is often not possible in a short time-frame. Another hurdle is the availability 
of reference materials (RMs) relevant for nanotechnology-based health products. Primary purpose 
of such RMs is to provide the confidence in measurements ensuring the quality of results. Lack of 
widely available, fit for purpose RMs can be an obstacle for the development of reliable methods for 
nanomaterial characterisation.
2Nanotechnology Characterization Laboratory (NCI-NCL): https://nanolab.cancer.gov/    
3European Nanomedicine Characterisation Laboratory (EUNCL): http://www.euncl.eu/
Currently a formal definition of nanomedicines does not exist. EMA has established a working definition 
for nanomedicines, based on following considerations (Pita, Ehmann, & Papaluca, 2016):
• Purposely designed systems for clinical applications
• At least one component at nano-scale size that should not exceed 1000 nm
• Resulting in definable specific properties and characteristics
Challenge 6:
Do we need to harmonise the terminology between the 
involved stakeholders?
Also the FDA has not established a regulatory definition of nanomaterials. In the guidance "Considering 
whether an FDA-Regulated Product involves the Application of Nanotechnology” (FDA, 2014a) it 
recommends to consider  specific questions which are applied broadly to all FDA-regulated products 
including medicinal products and medical devices (Box 7). 
The Nanomedicines Working Group of the International Pharmaceutical Regulators Programme (IPRP) 
(see Annex A.4) acknowledged the relevance of terminology for the harmonisation activities and 
included this topic in its work programme. The European Commission’s Joint Research Centre (JRC) 
is a member of the working group and took up the challenge to compile and analyse nanomedicine-
related terms and definitions used in regulatory context (Quiros-Pesudo et al., 2018). For this purpose 
websites of 13 regulatory authorities, all members of the IPRP Nanomedicines WG (see Figure 4) and 
international clinical trials registries have been crawled and text-mining tools were used to extract 
relevant information.
Key reference:
Pita et al (2016). Nanomedicines in the EU—Regulatory 
Overview. AAPS J. 18, 1576–1582. 
Box 7. Consideration of the US FDA on the application of nanotechnology (FDA, 2014a)
Whether a material or end product is engineered to have at least one external dimension, or an 
internal or surface structure, in the nanoscale range (approximately 1 nm to 100 nm);
Whether a material or end product is engineered to exhibit properties or phenomena, including 
physical or chemical properties or biological effects that are attributable to its dimension, even if 
these dimensions fall outside the nanoscale range, up to 1 μm (1000 nm).
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HC: Ottawa, 
Ontario (15,197)
Anvisa: Brasilia / Brazil
(472)
FDA: Silver 
Spring, MD
(76,754)
DG Grow: Brussels / BE (71,783)
DG Sante: Brussels / BE (3,383)
EMA: Amsterdam / NL (4,704)
Swiss Medic: Bern / CH (35,368)
TGA: Symonston / AU
(6,128)
MHWL: Tokyo / Japan (2,248)
MFDS: Cheongwon County / Korea (87)
TFDA: Taipei city (4,052)
HSA: Singapore (487)
Roszdravnadzor: 
Moscow / RU (70)
* including number of documents retrieved
Figure 4: Location of 13 regulatory authorities included in terminology study
The study demonstrated differences in number and type of terms used by regulatory authorities 
to describe nanomaterials used in health products. General terms such as nanomedicine(s), 
nanotechnology, nanomaterial, nanoscale and nanostructure were used by nearly every agency, in 
particular by EMA and FDA (Figure 5). 
Figure 5: Frequency of general terms in selected regulatory authorities’ websites
The analysis showed the existence of very specific terms used uniquely by certain regulatory 
authorities. Interestingly, the term “nanomedicines” was almost exclusively found in EMA’s documents 
to describe the application of nanotechnology in medicinal products, whereas other expressions, often 
related to terms like “nanomaterial” or “nanotechnology”, were preferred by several regulatory bodies 
(Table 4). 
The term “nanosimilar” was a specific term extracted from EMA’s website to describe the concept of 
nanomedicines that are claimed to be similar to a reference nanomedicine. Altogether, the JRC report 
showed geographical and sectorial differences in frequency and type of nanomedicine-related terms 
and compiled a set of most frequently employed terms to enable discussion and understanding 
among the stakeholders. However, further harmonisation of terminology between the regulatory 
authorities is needed to support marketing of nanotechnology-based products.
Table 4: Compilation of terms used by selected regulatory authorities (Quiros-Pesudo et al., 2018)
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The analysis showed the existence of very specific terms used uniquely by certain regulatory authorities. Interestingly, the 
term "nanomedicines" was almost exclusively found in EMA's documents to describe the application of nanotechnology in 
medicinal products, whereas other expressions, often related to terms like "nanomaterial" or "nanotechnology", were preferred 
by several regulatory bodies (Table 4).  
The term "nanosimilar" was a specific term extracted from EMA's website to describe the concept of nanomedicines that are 
claimed to be similar to a reference nanomedicine. Altogether, the JRC report showed geographical and sectorial differences 
in frequency and type of nanomedicine-related terms and compiled a set of most frequently employed terms to enable 
discussion and understanding among the stakeholders. However, further harmonisation of terminology between the 
regulatory authorities is needed to support marketing of nanotechnology-based products. 
Table 4: Compilation of terms used by selected regulatory authorities (Quiros-Pesudo et al., 2018). 
Source 
Main terms  
used to describe the application of nanotechnology 
to medical products 
Australia 
Therapeutic Goods Administration (TGA) 
Nanomedicines 
Therapeutic products containing nanomaterials 
Nanotechnology-based drug products 
European Union 
European Medicines Agency 
Nanomedicines 
Medicinal products containing nanoparticles
Nanomedicinal products 
Nanotechnology-based medicinal products 
Japan 
Pharmaceuticals and Medical Devices Agency, Japan 
(PMDA) 
Nanotechnology-based medicines 
Nanodrug delivery systems, 
Nanomedical devices 
Nanopharmaceuticals 
Nanosized drug 
United States 
US Food and Drug Administration (FDA) 
Nano-sized drug products 
Nanotechnology products 
Products that involve the application of nanotechnology 
Drug Products that Contain Nanomaterials 
Canada 
Government of Canada TERMIUM Plus®21 
Nanodrug 
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2.7 Harmonisation of regulatory practice
There is a general agreement in the international regulatory community that nanotechnology-enabled 
health products can be regulated according to existing legislative/regulatory frameworks. However, 
such frameworks might substantially vary in different geographical regions. Currently regulatory 
authorities are collaborating and seeking for the harmonization of regulatory practices in order to 
support the mutual acceptance of data in various regions.
EMA (EU), FDA (USA) and MHLW (Japan) have released specific guidance on data requirements for 
certain classes of nanotechnology-based products (Table 1). The Taiwan authority (TFDA) has added 
annexes to their current regulations for Registration of Medicinal Products related to: i) liposomal 
new drugs, ii) liposomal generic drugs. Health Canada provides some general considerations for 
nanomaterial-based products on their website and strongly recommends product developers to 
request a pre-submission meeting with the regulatory authority to discuss in details the information 
requirements that may be needed for the product seeking for regulatory approval. 
The recommendation on the early dialogue with the regulators is shared by the majority of regulatory 
agencies world-wide. Annex B.3 provides a short comparison of the regulatory frameworks in EU and 
US (Table B.2) that illustrates the various steps to be taken when seeking access to different markets 
(Marques et al., 2019). A parallel EMA-FDA scientific advice can be requested by product developers, 
especially in case of products being developed for indications lacking sufficient development guidelines. 
The Nanomedicines Working Group of the IPRP has been created as a platform to further facilitate 
an exchange of information and regulatory cooperation of the pharmaceutical regulatory bodies 
in different regions. A survey addressing the regulatory experience with liposomal products was 
performed among the members of the WG. The respondents have confirmed that a number of 
liposomal products have been approved under the current regulatory framework suggesting that 
no specific regulation is needed for this class of products. The most critical issues related to the 
regulation of liposomal products included:
• Approaches for regulation of follow on/generic liposomal medicines
• Correlation of in vitro and in vivo data 
• Limitations of analytical methodology
• Identification of quality attributes that are critical during the manufacturing process
• Selection of reference standards
The most common challenge, as recognised by respondents, is related to the regulation of generic 
liposomal products and, in particular, the comparability of data obtained with different measurement 
methods. Sharing of the submission data among the regulators could be of benefit in the identification 
of critical quality attributes. Developing a common definition of liposomes that would be acceptable 
for all regulators was suggested by the survey coordinators (IPRP, 2018b).
Challenge 7:
How can we harmonise regulatory practices at 
international level? 
3 Conclusions and 
perspectives
Nanotechnology-enabled health products have no particular legislative or regulatory framework and 
follow the current regulation of medicinal products or medical devices. However, the characteristics 
of nanotechnology-based products create some challenges when it comes to regulatory approval 
processes which are already recognized by regulatory authorities through the provision of initial 
reflection papers and guidance documents. Nevertheless, more efforts are needed to take up 
translational and regulatory science into academic research and educational programmes in order to 
support the development of regulatory structures that can be adaptive to the increasingly complex 
innovative health products (Figure 6). The present white paper highlights the major regulatory 
needs that require the development of additional guidance, methods and approaches in order to 
accommodate the particularities of nanotechnology-enabled products. 
1. Unclear information needs for innovative 
nanomedicines
Innovative products often challenge the regulatory framework since robust datasets guiding the 
regulatory needs for quality, safety and efficacy evaluation are lacking. A close monitoring of the 
scientific literature by e.g. using automated text mining tools, and in depth analysis of safety issues 
reported in real world databases, as well as a better balance on the need for information and a 
proactive pharmacovigilance/post-market surveillance coupled with a rapid reporting on adverse 
effects could be ways forward to break the vicious cycle of regulating innovative products.
2. Suitability and availability of methods, tools and 
approaches
The increasing complexity of innovative nanomedicinal products and their sophisticated manufacturing 
processes often require additional physicochemical characterisation steps or safety assessment in 
order to ensure the quality and safety of the products. However, existing characterisation methods 
are often not suitable to assess different types of nanomedicines or are not sufficiently standardised 
to be employed for the generation of the regulatory information. For certain specific areas no suitable 
methods are available at all, generating methodological gaps. Development and standardisation of 
lacking methods has been taken on board by the REFINE project and aims to benefit from the joint 
efforts of the method developers and standardisation communities. In addition, transferability of 
methods and standards from other sectors should be considered. 
3. Follow-on nanomedicines
Follow-on nanomedicines or "nanosimilars" are receiving more and more attention since patents of 
reference products are expiring but their complexity often does not allow a full comparability of 
physicochemical characteristics demonstrating the equivalence of the products. This group of products 
might require a new initiative that develops a regulatory framework allowing a demonstration of the 
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equivalence of the innovator products and the nanosimilars. The framework for assessing biosimilars 
could serve here as an example. 
4. Borderline and combination products
The regulatory path for nanotechnology-enabled products is not easy to determine when their primary 
mode of action is not obvious or when they are composed of two or more components that are 
regulated under various frameworks. 
Figure 6: Research needs for the advancement of the regulatory science in nanomedicine
More efforts are needed to take up translational and regulatory 
science into academic research and 
educational programmes in order to 
support the development of regulatory 
structures that can be adaptive to 
increasingly complex innovative health 
products.
5. Harmonisation 
As any other highly innovative product class also nanomedicines challenge the regulatory systems 
worldwide and the development of harmonised governance ensuring quick access to therapeutic 
solutions for medical needs should be considered. Under the umbrella of the International 
Pharmaceutical Regulators Programme representatives of competent authorities, the Nanomedicines 
Working Group has taken up the challenge. The group meets regularly in order to exchange the non-
confidential information regarding the regulation of nanomedicines, organise related workshops and 
training, support the efforts of the harmonisation of the terminology, and discuss methodologies used 
during the development and evaluation of nanomedicines.
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ANNEX A. Major organisations 
involved in the regulation of 
nanotechnology-enabled health 
products
A.1 European Medicines Agency (EMA)
The European Medicinal Agency (EMA) is a decentralised body of the European Union (EU), acting as 
interface between the national competent authorities rather than a centralised organisation. The EMA 
and the Community procedures of authorization of medicines for human and veterinary use have 
been established with the Regulation EEC2309/93. In accordance to Article 57 of the EC Regulation 
726/2004, EMA shall provide the Member States and the institutions of the Community with the best 
possible scientific advice on any question relating to the evaluation of the quality, safety and efficacy 
of medicinal products for human or veterinary use which is referred to it in accordance with the 
provisions of Community legislation relating to medicinal products.
EMA’s main responsibility is the protection and promotion of public and animal health by:
• Mobilizing the scientific resources available within the EU to guarantee a high qualitative level 
evaluation of medicinal products and to give advices on research and development programs;
• Defining efficient and transparent procedures for the marketing authorisation of both human 
and veterinary medicines;
• Checking upon the safety of medicines for human and veterinary use through a 
pharmacovigilance network.
EMA is structured in seven different scientific Committees:
• CHMP Committee for Medicinal Products for Human Use
• VMP Committee for Medicinal Products for Veterinary Use
• COMP Committee for Orphan Medicinal Products
• HMPC Committee on Herbal Medicinal Products
• PDCO Paediatric Committee
• CAT Committee for Advanced Therapies
• PRAC Pharmacovigilance Risk Assessment Committee
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The EMA Committee responsible for the evaluation and registration of new medicines is the CHMP. 
It is composed of 58 members: one member and an alternate nominated by each of the 27 Member 
States, one member and an alternate nominated by Iceland and by Norway; up to five co-opted 
members, chosen among experts nominated by Member States or the Agency and recruited, when 
necessary, to provide additional expertise in a particular scientific area and a chair, elected by CHMP 
members.
A.2 Notified Bodies (NBs)
Notified bodies are organisations designated by EU countries to assess the conformity of certain 
products before being placed on the market. These bodies carry out tasks related to conformity 
assessment procedures set out in the applicable legislation. The competence of NBs is periodically 
controlled by the competent authority and the European Commission publishes a list of notified bodies. 
Medical devices are assessed by NBs. The manufacturers are free to choose the notified body which 
will carry out the assessment procedure of their products. The issue of an EC certificate of conformity 
by an NB allows the product to be commercialized in all EU Member States. The NB-MED group 
allows NBs to share experience and exchange views, drafts technical recommendations and creates 
consensus on matters relating to conformity assessment and advises the European Commission at 
its request4.
A.3 Food and Drug Administration (FDA)
The Food and Drug Administration (FDA) is a US federal agency which has the role of protecting 
and promoting public health through the control and supervision of foods, drugs, vaccines, medical 
products and cosmetics. The agency is part of the United States Department of Health and Human 
Services which is one of the US federal executive departments.
Overall, the main roles of the FDA are:
• Promoting health by reviewing research and approving new products 
• Ensure that food and drugs are safe and properly labelled
• Working with other nations/organization to avoid worldwide public health threats
• Regulation of the manufacturing, marketing and distribution of products which can affect 
public health 
The agency is led by the Office of the Commissioner which reports directly to the secretary of Health 
and Human Services. The Office of the Commissioner hosts the chief scientist of the FDA who is 
responsible for the FDA Nanotechnology Task Force5. The mission of this Task Force is to identify 
and recommend ways to address any knowledge or policy gaps related to nanotechnology. All FDA 
offices and centres are contributing to the Nanotechnology Task Force which provides the overall 
4EC DG Grow –NB-MED group: https://ec.europa.eu/growth/sectors/medical-devices/new-regulations/dialogue-interested-parties_en 
5FDA Nanotechnology Task Force: https://www.fda.gov/science-research/nanotechnology-programs-fda/nanotechnology-task-force 
coordination of FDA’s nanotechnology regulatory science research efforts such as the Nanotechnology 
Core Facilities, training and professional development and opportunities for research excellence.
The Office of the Commissioner oversees four directorates:  
— Office of Foods and Veterinary Medicine
— Office of Medical Products and Tobacco
— Office of Global Regulatory Operations and Policy (GO)
— Office of Operations
The first two directorates are responsible for the assessment of the safety of specific products while 
the other two supports their efforts by drafting guidance, legislation and other general services.  More 
specific, the main mission of the Office of Foods and Veterinary Medicine is to promote public health 
by preventing foodborne illness, fostering good nutrition and improving safety and efficacy of animal 
health products. The Office of Medical Products and Tobacco provides advice to the Commissioner on 
all medical product related issues. Finally, the Office of Global Regulatory Operations and Policy and 
the Office of Operations, are in charge of supporting all the services across the FDA. The Office of 
Operations is also coordinating emergency involving FDA regulated products, such as post-marketing 
adverse events. The GO provides strategic leadership and oversight of the projects carried within the 
FDA, but also takes care of the global collaboration and the global data-sharing with other related 
agencies.  
The Office of Medical Products and Tobacco provides coordination across the centers for drugs, 
biologics, medical devices, and tobacco products and oversees the agency’s special medical programs. 
Following centers are a part of this directorate:
• Center for Biologics Evaluation and Research (CBER)
• Center for Devices and Radiological Health (CDRH)
• Center for Drug Evaluation and Research (CDER)
• Center for Tobacco Products (CTP)
• Office of Special Medical Programs 
• Oncology Center of Excellence
Several of those centers have regulatory science research programmes related to nanotechnology. 
Research projects cover novel detection technologies for pathogen, effects on carbon nanomaterials on 
blood cells (CBER), limitations of current test methods assessing quality and safety of nanomaterials 
(CDER), biocompatibility of nanomaterials (CDRH) etc.
A.4 EC DG GROW and the Medical Devices 
Coordination Group (MDCG)
The European Commission’s Directorate-General Internal Market, Industry, Entrepreneurship and 
SMEs (DG GROW) is responsible for coordinating the regulatory framework for medical devices. 
The Medical Devices Coordination Group (MDCG) is an expert group and was established by Regulation 
(EU) 2017/745 on medical devices and Regulation (EU) 2017/746 on in vitro diagnostic medical 
devices. Its members are experts representing competent authorities of the EU countries. The MDCG 
advises and assists the Commission and EU countries in the implementation of both Regulations.              
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The MDCG has 11 working groups6:
1. Notified Bodies Oversight (NBO)
2. Standards
3. Clinical investigation and evaluation (CIE)
4. Post-market surveillance and vigilance (PMSV)
5. Market surveillance
6. Borderline and classification (B&C)
7. New technologies
8. EUDAMED
9. Unique device identification (UDI)
10. International matters
11. In vitro diagnostic medical devices (IVD)
A.5 Competent authorities for medical devices 
(CAMD)
All European Competent Authorities (CAs) work together in the Competent Authorities for Medical 
Devices (CAMD) network to promote patient safety through the consistent development and 
application of the medical devices regulatory system7. The CAMD facilitates the implementation and 
the enforcement of the MDR and IVDR. It also provides training and exchange of best practices. The 
CAMD meetings are also networking events and may tackle medical device issues beyond the MDR and 
IVDR. As part of the implementation phase a consistent and harmonised approach in interpretation of 
the regulations across the network is fundamental to ensure consistency in the application of these 
regulations. The objective is to implement an effective, robust, predictable and secure regulatory 
system and ensuring better protection for public health in the medical devices sector. In order to 
achieve this, the CAMD developed a Roadmap (CAMD Implementation Taskforce, 2018).
A.6 International Pharmaceutical Regulators 
Programme (IPRP)
“The purpose of IPRP is to create an environment for its regulatory members and observers to 
exchange information on issues of mutual interest, enable cooperation and promote convergence of 
regulatory approaches for pharmaceutical medicinal products for human use”8.
IPRP has been created as a platform to facilitate an exchange of information and regulatory cooperation 
of the pharmaceutical regulatory bodies in different regions. Its mission is to coordinate international 
efforts related to regulation of medicines, and to harmonise guidelines for pharmaceuticals for 
6EC DG Grow- MDCG Group: https://ec.europa.eu/growth/sectors/medical-devices/new-regulations/dialogue-interested-parties_en  
7CAMD: https://www.camd-europe.eu/         
8IPRP: https://www.iprp.global/home
human use. Several Working Groups (WGs) dealing with specific topics have been created within this 
regulatory platform. They include: 
— Biosimilars WG
— Bioequivalence for Generics WG
— Cell Therapy WG
— Gene Therapy WG
— Information Sharing for Generics WG
— Quality for Generics WG
— Identification of Medicinal Products WG
— Nanomedicines WG 
IPRP Working Group on Nanomedicines was established in 2009 to discuss regulatory challenges 
related to products containing materials in nanoscale (IPRP, 2018a). The objectives of the IPRP 
Nanomedicines WG include:
• Sharing of the non- confidential information and regulatory harmonization in the area of 
nanomedicines / nanomaterial in drug products and borderline and combination products
• Regulatory cooperation with other related international bodies, particularly in specific topics 
of nanomedicines / nanomaterial in drug products
• Collaboration in the area of training/experience sharing among international regulators 
• Promotion of potential consensus finding on standards 
Discussions among participating entities are organised in the form of 2-3 face-to-face meetings/
teleconferences per year. The specific topics of interest recently taken on board by IPRP Nanomedicines 
WG include:
o Terminology, definitions and classifications
o Regulation of generic nanomedicines (“nanosimilars”)
o Critical quality attributes for nanotechnology-enabled medicinal products
Up to now the information exchange was practised among the members in terms of definitions and 
classification of nanomedicines, existence of specific guidance documents, legislation applicable to 
nanomedicines as well as workshops and training activities.
A.7 International Medical Device Regulators 
Forum (IMDRF)
IMDRF is a forum of medical devices regulators established to discuss the future directions of 
regulatory harmonisation in the field of medical devices. It was established in October 2011 and 
gathers currently the medical devices regulatory authorities from: Australia, Brazil, Canada, China, 
Europe, Japan, Russia, Singapore, South Korea, and United States of America.
Several Working Groups operate on specific activities identified in the IMDRF work plan. IMDRF 
Management Committee provides guidance on strategies, policies, directions, membership and 
activities of the Forum and oversees the activities of WGs. Topics including: the improvement of the 
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quality of the international standards, good regulatory review practice and guidance for Personalized 
Medical Devices are among current activities of the WGs.
A.8 International Council for Harmonisation 
of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) 
International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals 
for Human Use (ICH) is unique in bringing together the regulatory authorities and pharmaceutical 
industry to discuss scientific and technical aspects of drug registration. Hence their main focus is the 
drafting of international harmonized guidelines, e.g. related to the requirements for the validation 
of an analytical procedure. The guidelines describe the general aim of a given analytical procedure 
and provide a set of acceptance criteria. However, they do not describe any method as a technical 
standard in any detail. The ICH guidelines often build the foundation of guidelines release by national 
regulatory bodies, which means that the basic principles are internationally harmonised. The 
harmonisation is achieved through development of the Guidelines on Quality, Safety and Efficacy as 
well as Multidisciplinary aspects of pharmaceutical product evaluation (Table A.1). The activities are 
divided into four categories:
1) Formal ICH Procedure, for new topics of the harmonisation
2) Q&A Procedure
3) Revision Procedure and 
4) Maintenance Procedure, 
The last three are related to the revision and maintenance of the existent ICH Guidelines. Furthermore, 
as a part of the harmonisation process and the implementation of developed guidelines, the training 
activities related to different technical/scientific aspects are organised for ICH members and managed 
by the ICH Training Subcommittee. The ICH guidelines are relevant for information requirements for 
all medicinal products including nanomedicines.
Multidisciplinary guidelines are related to cross-cutting topics which do not fit into one of the Quality, 
Safety and Efficacy categories.  One of them (M4) is dedicated to the assembly of all collected data 
on quality safety and efficacy of the product into the common format called Common Technical 
Document (CTD), required for the submission to different regulatory authorities. The ICH M4 contains 
several parts related to the organisation (M4 (R4)), quality ((M4Q(R1)), safety (M4S(R2)) and efficacy 
(M4E(R2)) sections of the CTD. In addition M8 Guideline is dedicated to the constitution of CTD in 
electronic format (eCTD).
The Safety Guidelines cover different aspects of toxicity testing, covering specific health risks such 
as carcinogenicity, genotoxicity or reproductive toxicology. They address mainly nonclinical studies, 
discussing the suitability of in vivo and in vitro models. More general guidance on “Nonclinical Safety 
Studies” (M3) which supports the design and timely management of the nonclinical studies and helps 
to reduce the use of animals in accordance with the 3R (reduce/refine/replace) principles is part of the 
Multidisciplinary Guidelines. The Efficacy Guidelines refer to design, conduct and reporting of clinical 
trials organised in 19 specific topics.
The Quality Guidelines cover different parts of the product development and manufacturing, use of 
the validated analytical methods and evaluation of the critical quality parameters such as stability 
Table A.1: ICH Guidelines on Quality, Safety, Efficacy and Multidisciplinary topics
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Table A.1: ICH Guidelines on Quality, Safety, Efficacy and Multidisciplinar  topics. 
Quality Guidelines Efficacy Guidelines 
Q1: Stability 
Q2: Analytical Validation 
Q3: Impurities 
Q4: Pharmacopoeias 
Q5: Quality of Biotechnological Products 
Q6: Specifications 
Q7: Good Manufacturing Practice 
Q8: Pharmaceutical development 
Q9: Quality Risk management 
Q10: Pharmaceutical Quality System 
Q11:Development and Manufacture of Drug Substances 
Q12: Lifecycle Management 
E1:Clinical Safety for Drugs used in Long-Term Treatment 
E2: Pharmacovigilance 
E3: Clinical Study Reports 
E4: Dose-Response Studies 
E5: Ethnic Factors 
E6: Good Clinical Practice 
E7: Clinical Trials in Geriatric Population 
E8: General Considerations for Clinical Trials 
E9: Statistical Principles for Clinical Trials 
E10: Choice of Control Group in Clinical Trials 
E11: Clinical Trials in Pediatric Population 
E12: Clinical Evaluation by Therapeutic Category 
E14: Clinical Evaluation of QT 
E15:Definitions in Pharmacogenetics / Pharmacogenomics 
E16: Qualification of Genomic Biomarkers 
E17: Multi-Regional Clinical Trials 
E18: Genomic Sampling 
E19: Safety Data Collection 
Multidisciplinary Guidelines Safety Guidelines 
M1: MedRA Terminology 
M2: Electronic Standards 
M3: Nonclinical Safety Studies 
M4: Common Technical Document 
M5: Data Elements and Standards for Drug Dictionaries 
M6: Gene Therapy 
M7: Genotoxic Impurities 
M8: Electronic Common Technical Document (eCTD) 
M9: Biopharmaceutics Classification System-based Biowaivers 
M10: Bioanalytical Method Validation 
S1: Carcinogenicity Studies 
S2: Genotoxicity Studies 
S3: Toxicokinetics and Pharmacokinetics 
S4: Toxicity Testing 
S5: Reproductive Toxicology 
S6: Biotechnological Products 
S7: Pharmacology Studies 
S8: Immunotoxicology Studies 
S9: Nonclinical Evaluation for Anticancer Pharmaceuticals 
S10: Photosafety Evaluation 
S11: Nonclinical Paediatric Safety 
Multidisciplinary guidelines are related to cross-cutting topics which do not fit into one of the Quality, Safety and Efficacy 
categories.  One of them (M4) is dedicated to the assembly of all collected data on quality safety and efficacy of the product 
into the common format called Common Technical Document (CTD), required for the submission to different regulatory 
authorities. The ICH M4 contains several parts related to the organisation (M4 (R4)), quality ((M4Q(R1)), safety (M4S(R2)) and 
or purity. They include 12 main quality-related topics. No topics are related to evaluation of products 
containing nanomaterials.
The Q4 topic refers t  the ha moni ation f the pharmacopoeial standards in different regions. 
Three pharmacopeial organisations: American Pharmacopeia (USP), Japanese Pharmacopoeia (JP) 
and European Pharmacopoeia (Ph. Eur.) carry out their harmonisation efforts through a tripartite 
pharmacopeial harmonisation program known as the Pharmacopoeial Discussion Group (PDG). The 
work focuses mainly on the harmonisation of pharmacopoeial monographs, including excipient 
monographs and selected general chapters, in order to enable their recognition by regulatory 
authorities in the ICH regions.          
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A.9 National Pharmacopoeias and 
International Pharmacopoeia (Ph. Int.)
The pharmacopoeias are ensuring that marketed medicines are of good quality through:
• Quality standards for active substances
• General standards for dosage forms
• General standards for manufacture of medicines
• Monographs on finished products
• Standard terminology
Historically, all countries in Europe produced and maintained their own national pharmacopoeias. 
After World War II, the countries replaced their national pharmacopoeias with the European 
Pharmacopoeia. Other regions also retain their own common pharmacopoeias (for instance the 
United States Pharmacopoeia, USP). Since 1952, the World Health Organization (WHO) has published 
the International Pharmacopoeia with the aim to achieve a wide global harmonization of quality 
specifications for selected pharmaceutical products, excipients and dosage forms. 
Today, the International Pharmacopoeia focuses mainly on the WHO list of essential medicines and 
priority medicines of major public-health importance.
A.10 European Directorate for the Quality 
of Medicines (EDQM) and the European 
Pharmacopoeia (Ph. Eur.) 
“The European Pharmacopoeia is a single reference work for the quality control of medicines in the 
signatory states of the Convention on its elaboration. The official standards published within provide 
a legal and scientific basis for quality control during the development, production and marketing 
processes. They concern the qualitative and quantitative composition and the tests to be carried 
out on medicines, on the raw materials used in production of medicines and on the intermediates of 
synthesis. All producers of medicines and/or substances for pharmaceutical use must therefore apply 
these quality standards in order to market their products in the signatory states of the Convention”9. 
The European Pharmacopoeia contains a series of general monographs for the manufacturing of 
medicines, general methods of analysis of substances and medicines, and some general requirements 
for dosage forms (tablets, capsules, injections, etc.). The methods of analysis may also be used by the 
pharmaceutical industry for substances and medicines not described in the pharmacopoeia.
The bulk of the Ph. Eur. is made up of quality standards, which are noted both in the monographs and 
general methods sections. Quality standards contain analytical methods to identify the substance 
and evaluate its quality and quantitative strength. 
The EDQM has established a concept named certificate of suitability (CEP). A manufacturer of an 
active substance may apply to the EDQM for such a certificate. The application should contain a full 
description of the chemical synthesis of the substance, any potential and actual impurities. If the 
9EDQM: www.edqm.eu/en/european-pharmacopoeia-background-50.html
manufacturer can show that the quality of a substance is regulated by the Ph. Eur. monograph, the 
EDQM will grant a CEP. The CEP is included in the dossier for the Marketing Authorization Application 
(MAA). The regulatory authorities will accept the CEP as sufficient documentation that the Ph. Eur. 
monograph is fully capable of controlling the quality of the active substance.
A.11 US Pharmacopeia (USP)
USP develops and publishes standards for drug substances, drug products, excipients, and dietary 
supplements in the United States Pharmacopeia–National Formulary (USP–NF)10. These standards 
have been recognized in the Federal Food, Drug and Cosmetic (FD&C) Act since it was first enacted 
in 1938. The FD&C Act defines the term “official compendium” as the official USP, the official NF, 
the official Homeopathic Pharmacopeia of the United States, or any supplement to them. USP 
has no role in enforcement of these or other provisions that recognize USP–NF standards, which 
is the responsibility of FDA and other government authorities in the United States and elsewhere. 
Manufacturers and potentially affected parties are encouraged to contact FDA with questions about 
the specific applicability of USP standards to their products.
Specific Drug Categories and Topics:
• Drugs: USP’s goal is to have substance and preparation (product) monographs in USP–NF 
for all FDA-approved drugs, including biologics, and their ingredients. Although submission of 
information needed to develop a monograph by the Council of Experts is voluntary, compliance 
with a USP–NF monograph, if available, is mandatory in the following respects:
o Nonproprietary Name: under the relevant FD&C Act provisions, a drug will be deemed 
misbranded unless its label bears to the exclusion of any other nonproprietary name the 
“established” name.
o Identity: a drug with a name recognized in USP–NF must comply with the identity/
identification requirements of its monograph, or be deemed adulterated, misbranded, or 
both.
o Strength, Quality, Purity: drugs also must comply with compendial standards for 
strength, quality, and purity (tests for assay and impurities), unless labelled to show all 
respects in which the drugs differ.
o Packaging, Labeling: drugs with a name recognized in USP–NF also will be considered 
misbranded unless they meet compendial standards for packaging and labelling.
• Biologics: In the United States, all biologics are considered a subset of drugs, approved by 
FDA. All biologics are subject to the drug regulatory requirements. They are required to comply 
with the adulteration and misbranding provisions.
• Compounded Preparations: Compounding means the preparation, mixing, assembling, 
altering, packaging, and labelling of a drug, drug-delivery device, or device in accordance with 
a licensed practitioner’s prescription, medication order, or initiative based on the practitioner/
patient/pharmacist/compounder relationship in the course of professional practice. USP 
provides both general chapters and monographs for compounded preparations. Compounded 
preparation monographs include formulas (ingredients and quantities), specific directions to 
correctly compound the particular preparation, packaging and storage information, labeling 
information, pH, beyond-use dates based on stability studies, and detailed assays (majority of 
monographs).           
10USP-NF: www.uspnf.com/
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A.12 ASTM International
ASTM International is a non-profit organisation that develops and publishes technical standards. Of 
particular relevance is the ASTM Committee E56 on Nanotechnology which includes 170 members 
from 17 countries. The main objectives of the Committee E56 are the development of standards 
and guidance for nanotechnology and nanomaterials as well as the coordination of existing ASTM 
standardization related to nanotechnology needs. Today already 19 active standards have been 
developed and 13 additional are drafted. The technical Subcommittee E56.08 on Nano-Enabled 
Medical Products11 has released a number of different standards relevant for nanomedicines.
Generally, each member of ASTM International can propose a new standard following the ASTM 
process: 
1. Recognising the need: contacting the ASTM
2. Work Item Registration: The proposal is approved by sub chair or at a meeting
3. Task Group: drafting of a documentary standard by a group formed typically out of 6-8 key 
stakeholders 
4. Subcommittee Ballot: Bring in more experts: electronic ballot system to vote on the draft standard. 
Negative votes and comments must be addressed in order to proceed to the next stage.
5. Main Committee (Society Review): voting on standard, addressing any negative feedback or 
comments, back to subcommittee if needed.
6. ASTM International Committee on Standards: Review and Approval
7. Online and Print Publication: the draft will be published 6 weeks after the approval
8. Marketplace Use: Manufactures, 
governments, trade associations, 
consumers 
In order to support standardisation studies, 
ASTM has established an international Inter-
Laboratory Study programme (ILS) (Figure 
A.1) that facilitates the production of data 
to develop precision and bias statements as 
well as offering administrative support for the 
ongoing projects. 
11ASTM Subcommittee E56.08: www.astm.org/COMMIT/SUBCOMMIT/E5608.htm
Figure A.1: Steps in inter-
laboratory study program to 
assess the precession of a newly 
developed documentary standard 
within ASTM International
source: ASTM International
https://www.astm.org/
A.13 Comité Européen de Normalisation (CEN)
“CEN, the European Committee for Standardization, is an association that brings together the National 
Standardization Bodies of 34 European countries. CEN is one of three European Standardization 
Organizations (together with CENELEC and ETSI) that have been officially recognized by the European 
Union and by the European Free Trade Association (EFTA) as being responsible for developing and 
defining voluntary standards at European level."12
The development of European standards and other technical documents in relation to various kinds 
of products, materials, services and processes will protect consumers and facilitates cross-border 
trade. European standards for medical devices developed under a special mandate provided by the 
European Commission, the so-called harmonized standards, provide a presumption of conformity with 
the regulatory requirements. Through their more than 20 Technical Committees dedicated to medical 
equipment, CEN and CENELEC develop European Standards setting safety, quality and performance 
requirements for medical devices that are placed on the European market13. A large number of them 
enable manufacturers to make their medical products compliant with the European legislation in 
the medical sector, for the ultimate benefit of all European citizens. The Technical Committee on 
Nanotechnologies (CEN/TC 352)14 is coordinating the development of technical specifications in 
relation to various aspects on nanotechnologies. Standards are often developed in cooperation with 
ISO and IEC; the process of the standardisation is described in the paragraph on ISO (see annexe 
A.14).
A.14 International Organization 
for Standardization (ISO)
ISO is an independent, non-governmental 
international organization with a membership of 162 
national standards bodies. Through its members, 
it brings together experts to share knowledge and 
develop voluntary, consensus-based, market relevant 
International Standards that support innovation and 
provide solutions to global challenges. The Technical 
Committee on Nanotechnologies (ISO/TC 229)15 
has been established in order to develop standards 
for terminology and nomenclature; metrology and 
instrumentation; test methodologies; modelling 
and simulations; as well as science-based health, 
safety and environmental practices. The Figure A.2 
demonstrates the general process of developing a 
new ISO standard.     
        
12CEN: https://www.cen.eu/about/Pages/default.aspx       
13CEN-CENELEC sectors- medical devices:         
https://www.cencenelec.eu/standards/Sectorsold/healthcare/MedicalDevices/Pages/default.aspx    
14CEN/TC 352: www.cencenelec.eu/research/tools/horizon2020/industrialleadership/nanotech/pages/default.aspx  
15ISO/TC 229: www.iso.org/committee/381983.htm
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A.15 Organisation for Economic Co-operation 
and Development (OECD)
Organisation for Economic Co-operation and Development (OECD) mainly focuses on the 
characterisation of chemicals and especially the determination of their toxicity. This series is well 
established and has a wide acceptance and usage for the general assessment of any given chemical. 
The standards are also reviewed, revised, withdrawn, if needed, or updated with new ones on a 
regular basis. In order to ensure the safety of manufactured nanomaterials, the OECD established 
the Working Party on Manufactured Nanomaterials (WPMN) and launched a strategic programme on 
the safety evaluation and risk assessment of manufactured nanomaterials16 to assist countries in 
the implementation of national policies. Nevertheless, their main focus is on chemical products and 
not medical devices or medicinal produces. Therefore, these documentary and technical standards do 
not consider all the special requirements, which would be emphasised in the medical area. Even so 
they are well founded and often provide a good basis to develop an analytical procedure designed for 
medical products or devices. 
16Testing Programme of Manufactured Nanomaterials:        
http://www.oecd.org/chemicalsafety/nanosafety/testing-programme-manufactured-nanomaterials.htm
Figure A.2: Flow-chart illustrating 
main stages in the process developing 
a new ISO-standard
source: International Organisation for 
Standardisation:
https://www.iso.org/developing-
standards.html
A.16 Comparison of standardization 
requirements of ASTM and ISO
Some of the presented standardization bodies such as CEN or ISO will often focus on published 
procedures and results during the drafting of a new documentary standard, whereas others (e.g. 
ASTM International, OECD) will require more often testing of the draft technical standard in an inter-
laboratory study (ILS). Such an ILS provides benchmarks for the within laboratory repeatability and 
between laboratory reproducibility. Especially the later process of ILS supports regulatory bodies in 
their assessment of new documentary standards. But even if the actual development process of the 
various standardisation bodies is quite different (Table A.2) the key principles are the same (Box A.1). 
Technical standards of ISO and ASTM International are reviewed every five years to either prolong 
them for another five years, to revise them, or to withdraw them, because they are outdated or not 
anymore in demand. 
Box A.1 Common standardisation principles
• Standards respond to a need in the market
• Standards are based on expert opinion
• Standards are developed through a multi-stakeholder process
• Standards are based on a consensus
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Table A.2: Comparison between ASTM international and ISO. 
 
ASTM international ISO 
 A = American I = International 
How financed Sales of standards 
National members pay subscriptions that 
meet the operational cost of the Central 
Secretariat. The subscription paid by each 
member is in proportion to the country's 
Gross National Income 
Membership Open to all Via country standards organization 
Voting One member = One vote One country = One vote 
Balance Balance between producers, users, 
consumers 
 
Consensus 100% All negatives must be 
addressed 
Majority based on stage of standard 
Number of Committees 140 250 
Number of members 32000 individual members 160+ countries 
Number of Active 
Standards 12000 21000 
Nanotechnology E56 (2005) TC229 (2006) 
Meeting Twice yearly Twice yearly 
Precision & Bias Mandatory Desirable 
ILS Yes Use OECD and other groups and perform 
own ILS sometimes 
Minimum Balloting time 30 days 3 months + 
Meetings International (1/4 must be outside the 
US) 
International 
Famous For ASTM E11 Sieves ISO9000+, ISO17025 
Other Collaboration spaces; Standardization 
News 
 
HQ West Conshohocken, PA, USA Geneva, Switzerland 
  
Table A.2: Comparison between ASTM international and ISO ANNEX B. Regulatory 
frameworks relevant for 
nanotechnology-enabled health 
products 
The following section gives an overview on the regulatory frameworks involved in the approval of 
nanotechnology–enabled health products. It needs to be pointed out that no dedicated framework 
for such products exists and products are regulated within the current regulatory frameworks of 
medical devices and medicinal products. However, products that are very similar to such health 
products can also fall under other sectorial legislations such as cosmetic products or novel foods. For 
such “borderline” products, their classification must be made on a case-by-case basis (Council of the 
European Communities, 1976; EC, 2001). 
B.1 European regulatory framework for 
medicinal products 
The European Regulatory Framework for medicinal products is based on Directive 2001/83/EC on 
Medicinal Products for Human Use (EC, 2001), which regulates the European marketing authorization 
and is supplemented with Directives, Commission regulations and several legal reference documents. 
Furthermore, this Directive is supported by a large number of scientific guidelines but none of them 
is related to nanotechnology-enabled medicinal products. 
EMA has released a number of Reflection Papers related to different categories of nanotechnology-
based products in order to provide initial guidance on the assessment of their quality and safety (see 
Table 1). EMA’s Innovation Task Force is monitoring the field and organizes regulatory awareness 
sessions in order to update assessors on the progress in regulatory science in the field of nanomedicine. 
The scientific advice procedures offer individual support for the development of nanomedicines.
The successful development and commercialization of a nanomedicinal product depends on the 
complex interplay of actions by different actors: researchers, funders, pharmaceutical companies, 
regulators, standardisation bodies and institutions as for any other innovative health product. The 
development stage takes an average of 10-15 years and includes preclinical studies, clinical studies 
and the registration process (Figure B.1). 
The final step of the drug development process, after successful completion of Phase 3 trial, is the 
request of registration of use of a compound for specific indication(s) in a specific market by a 
pharmaceutical company. Different types of registrations are possible within the existent regulatory 
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framework: National Procedure, Centralised Procedure and Mutual Recognition procedure. While the 
National Procedure enables an authorisation in one Member State, the Centralised Procedure allows 
the applicant to obtain an authorisation valid for all Member States of the European Union, after a 
positive evaluation of the EMA. If a medicinal product has already been authorised through National 
Procedure in one Member State and the industry wants to extend the marketing authorisation to other 
Member States the Mutual Recognition procedure can be used.
Figure B.1: Main phases of a drug development process, comprising the design phases (light blue), preclinical phases 
(dark blue) and clinical trial stages (green) leading to marketing authorisation
The compilation of dossiers for applications for European Marketing Authorisation should be made 
entirely in accordance with the rules of the Common Technical Document (CTD). The CTD is an 
international format, assembling all quality, safety and efficacy information, as described in ICH M4 
guideline (ICH, 2002). In addition, applicants are obliged to take into account the Community guidelines 
relating to the quality, safety and efficacy of drug/medicinal products published by the Commission in 
“The rules governing medicinal products in the European Community”, Volumes 3A, 3B, 3C: Guidelines 
on the quality, safety and efficacy of medicinal products for human use.
Once on the market, the product safety is to be continuously monitored as a part of the pharmacovigilance 
procedure, defined as “the science and activities relating to detection, assessment, understanding 
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and prevention of adverse effects or any other medicine-related problem”. In the EU the EMA is 
responsible for the coordination of the pharmacovigilance system and supporting relating activities. 
In addition to EMA, marketing authorization holders and national competent authorities are involved 
in operating the pharmacovigilance system. 
Reports of suspected adverse reactions seen in healthcare practice or clinical trials are stored in 
EudraVigilance system managing information on suspected adverse reactions to medicines which 
have been authorised or are being investigated in the European Economic Area (EEA). EMA’s 
Pharmacovigilance Risk Assessment Committee (PRAC) is responsible for assessing and monitoring 
the safety of human medicines. It evaluates signals coming from EudraVigilance and may recommend 
a regulatory action.
B.2 Medical devices: European regulation and 
classification scheme
For many years, three Directives have covered medical devices, namely the Active Implantable Medical 
Devices Directive 90/385/EEC (AIMDD), the Medical Devices Directive 93/42/EEC (MDD) and the In-
Vitro Diagnostic Medical Devices Directive 98/79/EC (IVDD). These Directives are supplemented by 
15 amending or implementing legislative documents. This regulatory framework on medical devices 
does not contain specific requirements regarding nanomaterials.
On 5 May 2017, two new regulations on medical devices were published: the Medical Devices Regulation 
(EU) 2017/745 (MDR) and the In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 (IVDR). 
The IVDD will be replaced by the IVDR in May 2022, after a transition period of 5 years. This regulation 
does not contain any content specifically related to nanomaterials. 
In May 2020, after a transition period of 3 years, the AIMDD and the MDD will be replaced by the 
MDR (EU, 2017). This regulation does contain several provisions on nanomaterials. It also contains 
a definition for nanomaterials, which will be discussed in a separate section below. This definition 
can be amended, reflecting technical or scientific progress as well as new European or international 
definitions. 
According to article 5 (2) in the MDR, a device shall meet the general safety and performance 
requirements set out in Annex I. One of these requirements is that a device shall be designed and 
manufactured in such a way as to reduce as far as possible the risks linked to the size and the 
properties of particles which are or can be released into the patient’s or user’s body, unless they come 
into contact with intact skin only. Special attention shall be given to nanomaterials. This requirement 
will most logically be addressed as part of the biological evaluation of medical devices. The EN ISO 
10993 series of standards provides a framework on how to perform a biological evaluation. It includes 
a systematic approach to deciding which biological endpoints need to be addressed for a particular 
device. Furthermore, it prescribes methods for physicochemical characterisation of the devices and 
their potential degradation products. It also prescribes the relevant assays for the various biological 
endpoints. In 2017, a separate guidance document was added as part 22 to the series in order to 
specify how the EN ISO 10993 series can be applied to medical devices containing or consisting of 
nanomaterials.
The MDR contains a classification system, similar to the MDD. Devices are classified as Class I, IIa, IIb 
or III. The higher the class, the more stringent the conformity assessment route to prove compliance 
with the regulation. For Class I, self-certification can be applied. For the higher classes, involvement of 
a Notified Body (organization certified by a Member State Competent Authority) is required to obtain 
a CE certification that will allow the manufacturer to place the device on the market. In the MDR, a 
new rule was introduced related to nanomaterials, Rule 19. This rule specifies that a medical device 
containing nanomaterials is classified as Class IIa if the potential internal exposure is negligible. 
Class IIb applies to medical devices for which the potential internal exposure to the nanomaterials is 
low, while medical devices which have a medium or high potential of internal exposure are classified 
in Class III. The regulation does not clarify the meaning of negligible, low, medium or high and how 
Key reference:
SCENIHR (2015). Opinion on the Guidance on 
the Determination of Potential Health Effects of 
Nanomaterials Used in Medical Devices. Final Opinion. 
https://doi.org/10.2772/41391
this should be applied in practice. Currently, 
guidance is being developed for this purpose 
by the European Commission WG on New and 
Emerging Technologies. 
An important document for the development 
of the guidance is the Scientific Committee on 
Emerging and Newly Identified Health Risks 
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(SCENIHR) opinion on the guidance on the determination of potential health effects of nanomaterials 
Table B.1: An estimation of potential internal exposure as starting point for a risk evaluation for medical devices containing nanomaterials.
Type of application of nanomaterials 
Internal exposure 
Free 
Fixed 
(coating) 
Fixed 
(coating) 
Embedded Embedded 
Type of device 
Type of 
contact 
Duration of 
contact 
Weak 
(physisorb) 
Strong 
(chemisorb) 
In 
degradable 
materials* 
In non- 
degradable 
materials 
Surface 
device 
Intact skin 
≤ 24 h N N N N N 
>24 h to 30 d N N N N N 
>30 d N N N N N 
Intact mucosal 
membrane 
≤ 24 h L L N L N 
>24 h to 30 d M M L M N 
>30 d M M L M N 
Breached or 
compromised 
surface 
≤ 24 h H M L M N 
24 h to 30 d H M L M N 
30 d H M L M N 
External 
Communicating 
device 
Blood path, 
indirect ** 
≤ 24 h na M L L N 
>24 h to 30 d na M L M N 
>30 d na M L M N 
Tissue/bone/ 
dentin 
≤ 24 h H M L L N 
>24 h to 30 d H M L M N 
>30 d H M L H N 
Circulating 
blood*** 
≤ 24 h na H H L N 
>24 h to 30 d na H H M N 
>30 d na H H H N 
Implant 
device 
Tissue/bone 
≤ 24 h H H L L N 
>24 h to 30 d H H L M N 
>30 d H H L H N 
Blood 
≤ 24 h H H L L N 
>24 h to 30 d H H L M N 
>30 d H H L H N 
H=high, M=medium, L=low, N=negligible, na= not applicable; 
* the exposure will depend on the degradation time of the medical device,
** contacting the blood path at one point. Examples of these types of devices are solution administration sets, transfer sets and blood administration sets 
(ISO 10993-4:2002),  
*** Examples of these types of devices are: intravascular catheters, extracorporeal oxygenating tubing and dialyzers (ISO 10993-4:2002). 
Source: (SCENIHR, 2015) 
The type of device takes into consideration the application site. Devices that contact the skin are considered to lead to a lower 
potential internal exposure compared to external communicating devices (that come directly in contact with blood, tissue, bone 
or dentin) and implantable devices. The types of tissue contact considered in the risk assessment of the SCENIHR opinion 
include skin, mucosal membrane, breached/compromised surface, blood, tissue, bone and dentin. The longer the duration of 
contact with the body, the higher the potential for internal exposure with limited contact (≤ 24 hours) as the shortest exposure 
duration, followed by a prolonged contact (> 24 hours to 30 days) and permanent contact (<30 days). The internal potential 
exposure also depends on how the nanomaterials are incorporated in the medical device. Nanomaterials which are embedded 
in a non-degradable material possess a negligible potential for internal exposure, while the potential internal exposure is high 
if the nanomaterials are embedded in a degradable material. For nanomaterials that are used in coatings of medical devices, 
the potential internal exposure depends on how the nanomaterials are fixed. Thi s potential is lower if the nano-coating is 
chemically bound compared to when weaker physical bounds are applied. Medical devices that contain free nanomaterials 
show the highest potential internal exposure. 
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used in medical devices (SCENIHR, 2015), which introduced the concept of (external and) internal 
exposure. 
According to this opinion the potential exposure is dependent on the type of device, type of contact, 
duration of the contact and type of application of the nanomaterial (Table B.1). 
Table B.1: An estimation of potential internal exposure as starting point for a risk evaluation for medical devices 
containing nanomaterials
The type of device takes into consideration the application site. Devices that contact the skin are 
considered to lead to a lower potential internal exposure compared to external communicating 
devices (that come directly in contact with blood, tissue, bone or dentin) and implantable devices. 
The types of tissue contact considered in the risk assessment of the SCENIHR opinion include skin, 
mucosal membrane, breached/compromised surface, blood, tissue, bone and dentin. The longer the 
duration of contact with the body, the higher the potential for internal exposure with limited contact 
(≤ 24 hours) as the shortest exposure duration, followed by a prolonged contact (> 24 hours to 30 
days) and permanent contact (<30 days). The internal potential exposure also depends on how the 
nanom teri ls are incorporated in the medic l device. Nanom e ials which are e bed d in a non-
degradable material possess a negligible potentia  for internal exposure, hile the p tential internal 
exposure is high if the nanomate ials are embedded in a degradable ma erial. For n nomaterials 
that are used in coatings of medical devices, the potential internal exposure depends on how the 
nanomaterials are fixed. This potential is lower if the nano-coating is chemically bound compared to 
when weaker physical bounds are applied. Medical devices that contain free nanomaterials show the 
highest potential internal exposure.
B.3 Differences in the regulatory framework in 
Europe and US
Nanotechnology-enabled health products are regulated under existing regulatory frameworks for 
medicinal products and medical devices, which can substantially vary in different geographical 
regions. The short comparison of the regulatory frameworks in EU and US (Table B.2) should illustrate 
the various steps in the regulatory approval when seeking access to both markets. While in the US the 
FDA is the main actor involved in approval of preclinical and clinical studies and in the authorization of 
new medicines and medical devices, the situation in Europe is more fragmented and involves national 
competent authorities, Notified Bodies, expert panels, the EMA and European Commission (Table B.2). 
For example clinical trials are authorised by national competent authorities whereas the final market 
authorisations of innovative products such as nanomedicines are granted by the EMA. In contrary, the 
EMA is not involved in the regulation of medical devices, while FDA is the main responsible authority 
for medical devices commercialization in the US.
The manufacturer applies for the CE marking and Notified Bodies (NBs) (organizations certified by a 
Member State Competent Authority) are responsible for the conformity assessment. The EC, MDCG and 
CAMD all play their roles in this system (see Annex A). Furthermore, the classification into medicinal 
products and medical devices is crucial, since it determines the regulatory path the product should 
follow. However, as the definitions in different geographical regions can slightly differ, the products 
might be classified differently in various regions. The situation is even more complex for borderline 
products and combination products.
Both in Europe and US the determination of the primary mode of action (PMOA) is critical to decide 
which regulatory framework and which authority should be responsible for the product registration. 
However, in the US the primary responsibility for assigning combination products to a lead agency 
center is implemented by FDA Office of Combination Products (OCP). A formal request of determination 
of a combination product’s classification may be submitted to OCP which will determine the PMOA 
and assign the review responsibility to the corresponding FDA center. In Europe, in case of uncertainty 
Due to regional differences certain nanomedicines might fall 
under different regulatory frameworks resulting in slightly 
different regulatory requirements.
there is no clear procedure to follow and different regulatory authorities and NBs may be consulted 
by company in the early stage of the development process.
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Table B.2: Overview of major differences in the regulatory frameworks relevant for nano-enabled health products in EU and US. 
EU US 
Regulatory framework 
for nanomedicinal 
products 
Centralised marketing authorisation applications 
(MAA) to EMA Committee for Medicinal Products for 
Human Use  (CHMP) 
New Drug Application (NDA), Investigational New 
Drug (IND) or Abbreviated New Drug Application 
(ANDA) submitted to the FDA 
Center for Drug Evaluation and Research (CDER) 
Regulatory framework 
for nanomedical 
devices 
Applications are reviewed by Notified Bodies and in 
specific cases by expert panels. If the device meets 
regulatory requirements a CE mark is granted and 
the device can be commercialised in all member 
states. 
Application to FDA Center for Devices and 
Radiological Health (CDRH). Class III medical 
devices require a premarket approval (PMA) based 
on the review of safety and efficacy of a device. 
Classification of 
medicinal products 
and medical devices 
Mechanism of principal intended action 
(pharmacological, immunological or metabolic 
action is distinctive for medicinal products) 
Mechanism of action (chemical action or the fact 
of being metabolised by the body is distinctive for 
medicinal products) 
Combination products 
Several authorities (EMA ITF, national authorities, 
Notified Bodies) may be consulted in case of 
unclear regulatory pathway. 
FDA Office of Combination Products (OCP) is 
responsible for the product classification as a drug, 
device, or biologic based on the PMOA. 
Definition of 
nanomedicine 
Descriptor as agreed with Intl. 
Nanomedicines WG: 
 Purposely designed systems for
clinical applications 
 At least one component at nano
-scale size (1-1000nm) 
 Resulting in definable specific
properties and characteristics:
-related to the specific 
nanotechnology application and 
characteristics for the intended use 
(route of admin, dose) 
-associated with the expected clinical advantages
of the nano 
-engineering (e.g. preferential organ/tissue 
distribution) 
No regulatory definition, but points to 
consider per FDA finalized guidance “Considering 
whether an FDA-Regulated Product involves the 
Application of Nanotechnology: 
- Whether a material or end product is engineered 
to have at least one external dimension, or an 
internal or surface structure, in the nanoscale 
range (approximately 1 nm to 100 nm); 
- Whether a material or end product is engineered 
to exhibit properties or phenomena, including 
physical or chemical properties or biological effects 
that are attributable to its dimension, even if these 
dimensions fall outside the nanoscale range, up to 
1 μm (1000 nm). 
Regulatory advice 
Scientific advice procedure, which can be 
requested at any stage of development, helps to 
perform the appropriate tests and studies. 
Pre-IND meetings provide help in preparation of 
an IND application, exploring possibilities to 
enhance and support development. 
Both in Europe and US the determination of the primary mode of action (PMOA) is critical to decide which regulatory 
framework and which authority should be responsible for the product registration. However, in the US the primary 
responsibility for assigning combination products to a lead agency center is implemented by FDA Office of Combination 
Products (OCP). A formal request of determination of a combination product’s classification may be submitted to OCP which 
will determine the PMOA and assign the review responsibility to the corresponding FDA center. In Europe, in case of 
Both EMA and FDA provide regulatory and scientific help for applicants during the product development 
phase, regarding performing of appropriate tests and studies. The EMA’s scientific advice procedure 
has been often requested from companies developing nanotechnology-based medicines. Furthermore, 
a parallel EMA-FDA scientific advice can be requested by product developers, especially in case of 
products being developed for indications lacking development guidelines. This interaction should 
provide a better understanding of the regulatory framework.      
     
Table B.2: Overview of major differences in the regulatory frameworks relevant for nano-enabled health products in EU 
and US
B.4 Requirements for gaining regulatory 
acceptance of methods
Methods, tools and approaches providing information that allow regulators to make decisions on the 
assessment of the quality safety and efficacy of medical products need to be checked for their reliability 
and relevance for the intended purpose. As a first step novel methodologies can seek for feedback on 
their suitability for regulatory purposes by following a qualification process developed by EMA and 
the FDA (Table B.3).  Methods used in non-clinical or clinical studies, novel biomarkers, or models can 
undergo such a qualification procedure. Based on the submitted results and the recommendation of 
the Scientific Advice, the EMA CHMP can issue a qualification opinion on the acceptability of a specific 
use of a method. Alternatively it can provide a qualification advice supporting further development 
of a method towards its final qualification. Whereas the qualification process is an optional step, 
the following validation procedure is mandatory for gaining regulatory acceptance of a method. 
Guidance documents on the validation of analytical, bioanalytical procedures as well as on in silico 
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Whereas the qualification process is an optional step, the following validation procedure is mandatory for gaining 
regulatory acceptance of a method. Guidance documents on the validation of analytical, bioanalytical procedures as well as 
on in silico methods and in vitro methods were released by the regulatory authorities (Tables B.3 and B.5) and will be briefly 
presented.  
Table B.3: Guidance documents related to the qualification and validation of methods. 
Organisation References 
Method 
qualification 
EMA 
EMA/CHMP: Qualification of novel methodologies for drug development: guidance to 
applicants. EMA/CHMP/SAWP/72894/2008.(EMA/CHMP, 2014) 
FDA 
Guidance for Industry and FDA Staff: Qualification Process for Drug Development Tools 
(January 2015).(FDA, 2014b) 
Method 
validation 
EMA 
EMEA: Validation of Analytical Procedures: Text and Methodology (June 1995).(EMA, 1995) 
EMEA/CHMP. Guideline on bioanalytical method validation EMEA/CHMP/EWP/192217/2009 
Rev. 1 Corr. 2** (21 July 2011).(EMA/CHMP, 2011) 
FDA 
Analytical Procedures and Methods Validation for Drugs and Biologics Guidance for Industry 
(July 2015). (FDA, 2015) 
Guidance for Industry: Bioanalytical Method Validation. Draft Guidance (September 
2013).(FDA, 2013) 
ICH 
International conference of harmonisation of technical requirements for registration of 
pharmaceuticals for human use. ICH Harmonised Tripartite: Guideline Validation of Analytical 
Procedures: Text and Methodology Q2(R1) Current Step 4 version.(ICH, 2005) 
Validation of analytical and bioanalytical procedures 
Table B.4 describes a set of performance characteristics, which a given method has to achieve during validation. These 
parameters and their performance characteristics limits are independent of the investigated material or compound but are 
critical for the successful conduct of nonclinical and/or biopharmaceutics and clinical pharmacology studies.  Existing guidance 
on the method validation (Table B.3) refers to analytical procedures, necessary for the characterisation of the drug, or to 
bioanalytical methods providing quantitative evaluation of drugs, their metabolites (analytes) and biomarkers in a given 
biological matrix (e.g., blood, plasma, serum, or urine). 
The methods are further split into chromatographic and ligand binding analysis methods, which both have a full series of 
additional requirements and associated performance requirement limits. This results in a long list with further performance 
characteristic data, which also have to be reported in the validation report. 
Table B.4: Set of method characteristics required for the qualification and validation of (bio)analytical and in vitro methods (Ritter et al., 
2003). 
Requirements 
Qualification 
(all) 
Validation 
(analytical) 
Validation 
(bioanalytical) 
Validation (in vitro) 
Specificity/Selectivity X X X X 
Linearity/Range X X X X 
Accuracy X X X (X) 
m thods and in vitr  meth s were releas d by t e regulat ry uthorities (Tables B.3 and B.5) nd 
will be briefly presented. 
Table B.3: Guidance documents rel ted to the qualification and validation of methods
Validation of analytical and bioanalytical procedures
Table B.4 describes a set of performance characteristics, which a given method has to achieve during 
validation. These parameters and their performance characteristics limits are independent of the 
investigated material or compound but are critical for the successful conduct of nonclinical and/or 
biopharmaceutics and clinical pharmacology studies.  Existing guidance on the method validation 
(Table B.3) refers to analytical procedures, necessary for the characterisation of the drug, or to 
bioanalytical methods providing quantitative evaluation of drugs, their metabolites (analytes) and 
biomarkers in a given biological matrix (e.g., blood, plasma, serum, or urine).
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Table B.4: Set of method characteristics required for the qualification and validation of (bio)analytical and in vitro methods (Ritter et al., 
2003). 
 
Qualification and validation of in vitro and in vivo methods for safety evaluation 
As any other analytical methods also in vitro and in vivo methods can be subject to the qualification process of EMA. The 
qualification process requires information on the experimental approach including the selection of the biological model, 
positive and negative controls as well as a detailed description of the readout systems. The analytical/technological assay 
validation demands the assessment of repeatability (intra-run precision; intra-laboratory variability) and reproducibility 
(inter-lab precision) (Table B.4). In particular for sophisticated readout systems such as microfluidics, the sensitivity of assay 
parameter (ruggedness) has to be analysed and parameters such as e.g. on tubing, flow rate/sheer stress, cell number etc. 
have to be carefully controlled. Furthermore, the instrumentation as well as the statistical methodology has to be evaluated 
for their accuracy. 
The qualification of the proposed biological model requires a review on components such as the intra- and inter-animal 
variability, difference between species and strains for in vivo experiments whereas for in vitro methods the source and 
identity of cells, the reproducibility of the source as well as the biological relevance are decisive. When assessing biological 
effects triggered by nanomaterial, interaction with reagents have to be excluded. The submission dossier should be supported 
by a systematic review on the assays as well as a description of remaining gaps (EMA/CHMP, 2014).  
In the last decades in vitro methods were considered as a key component for the implementation of the 3Rs concept leading 
to a reduction of animal experiments. In this context stringent validation criteria have been developed in order to avoid an 
impact on safety and efficacy assessment. This is of particular importance when in vitro methods are considered as a 
replacement for an animal experiment and decision point in testing strategies and other regulatory decisions. In particular, the 
European Centre for the Validation of Alternative Methods (ECVAM) and its sister organisation the Interagency Coordination 
Committee on the Validation of Alternative methods (ICCVAM) have closely collaborated in order to develop harmonised 
Requirements 
Qualification 
(all) 
Validation 
(analytical) 
Validation 
(bioanalytical) Validation (in vitro) 
Specificity/Selectivity X X X X 
Linearity/Range X X X X 
Accuracy X X X (X) 
Precision (repeatability, 
intermediate precision, 
reproducibility ) 
X X X X 
Quantitation  limit 
 
X X 
 
Dynamic range/Detection 
limit  
X 
 
X 
Stability 
  
X 
 
Robustness 
 
(X) 
 
X 
Ruggedness 
   
X 
results in a long list with further performance characteristic data, which also have to be reported in 
the validation report.
Table B.4: Set of method characteristics required for the qualification and validation of (bio)analytical and in vitro 
methods (Ritter et al., 2003)
Qualification and validation of in vitro and in vivo 
methods f r safety evaluation
As any oth r a alytical methods also in vitro and in vivo methods c n be subject to the qualification 
process of EMA. The qu lification process requires information on the experimental approach including 
the selection of the biological model, positive and negative controls as well as a detailed description 
of the readout systems. The analytical/technological assay validation demands the assessment of 
repeatability (intra-run precision; intra-laboratory variability) and reproducibility (inter-lab precision) 
(Table B.4). In particular f r sophisti ted r adout systems such as microfluidics, the sensitivity of 
Key reference:
EMA/CHMP (2016). Guideline on the principles of 
regulatory acceptance of 3Rs (replacement, reduction, 
refinement) testing approaches. 
EMA/CHMP/CVMP/JEG-3Rs/450091/2012
The qualification of the proposed biological model requires a review on components such as the 
intra- and inter-animal variability, difference between species and strains for in vivo experiments 
whereas for in vitro methods the source and identity of cells, the reproducibility of the source as well 
as the biological relevance are decisive. When assessing biological effects triggered by nanomaterial, 
interaction with reagents have to be excluded. The submission dossier should be supported by a 
systematic review on the assays as well as a description of remaining gaps (EMA/CHMP, 2014). 
In the last decades in vitro methods were considered as a key component for the implementation 
of the 3Rs concept leading to a reduction of animal experiments. In this context stringent validation 
criteria have been developed in order to avoid an impact on safety and efficacy assessment. This 
is of particular importance when in vitro methods are considered as a replacement for an animal 
experiment and decision point in testing strategies and other regulatory decisions. In particular, the 
European Centre for the Validation of Alternative Methods (ECVAM) and its sister organisation the 
Interagency Coordination Committee on the Validation of Alternative methods (ICCVAM) have closely 
collaborated in order to develop harmonised criteria for method validation. 
These criteria are widely accepted by different industrial sectors not only for alternative methods 
(EMA/CHMP, 2016; Hartung et al., 2004; ICCVAM, 1997; OECD, 2005).
Already today a number of in vitro methods were successfully validated following the criteria developed 
by ECVAM and its partner. However, their applicability domain is mainly in the field of industrial 
chemicals and it remains an open question whether they are also suitable for the assessment of 
nanotechnology-enabled health products.
Qualification and validation of in silico methods
Physiologically-based pharmacokinetic (PBPK) modelling is now routinely utilised to aid an efficient 
and quantitative understanding of the pharmacokinetic-pharmacodynamic relationship of small-
molecule drugs and their metabolites. The tool has been increasingly recognised by regulatory bodies 
in recent years to facilitate drug development programs. In terms of nanomedicine development, 
the application of PBPK models for the informed simulation of first-in-human studies, drug-drug 
interactions, formulation changes and extrapolation to special populations can provide a substantial 
insight into the pharmacological behaviour of a nanomedicine compared to conventional drug. 
Although there are no specific guidelines on the use of PBPK in nanomedicine development, there 
is some guidance on the general use of PBPK analyses to support applications to regulatory bodies 
(Table B.5).
The EMA have drafted a guidance document describing the qualification and reporting of PBPK 
modelling and simulation approaches suitable for clinical development decision making (Table B.5). 
This document details the qualification of platforms suitable for PBPK and what is required in terms 
of model validation. For the general qualification of a PBPK platform i.e. a version of PBPK software 
for an intended purpose, this may be reviewed via a CHMP qualification procedure following the 
Qualification of novel methodologies for drug development guidelines (EMA/CHMP, 2014) (see section 
above). The predictive performance of the platform should then be further evaluated if it is to be used 
for an intended purpose (EMA/CHMP, 2018). This process should involve a detailed description of the 
model parameters, the equations used, how preliminary data was derived (if experimental) and a 
discussion on the source of any data collected from the literature. The requirements for qualification 
depend on the impending regulatory impact that data provided by the model may have if clinical 
decisions were to be made on its basis. This can be classified as high, moderate or low. The guidance 
recommends information should be provided on aspects of model structure, model performance in 
terms of sensitivity and level of confidence, and the final model results that should include a discussion 
of the simulation results and their regulatory consequences. There are a number of issues raised by 
academic and industry reviewers that mainly concern an uncertainty surrounding the qualification 
process where the regulators are advised to provide more detail in their requirements. For example, 
assay parameter (ruggedness) has to be 
analysed d parameters such as e.g. on 
tubing, flow rate/sheer stress, cel  number tc. 
h ve to be carefully controlled. Furthermore, 
the instrumentation as well as the statistical 
methodology has o be evaluated for their 
accura y.
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criteria for method validation.  These criteria are widely accepted by different industrial sectors not only for alternative 
methods (EMA/CHMP, 2016; Hartung et al., 2004; ICCVAM, 1997; OECD, 2005). 
Already today a number of in vitro methods were successfully validated following the criteria developed by ECVAM and its 
partner. However, their applicability domain is mainly in the field of industrial chemicals and it remains an open question 
whether they are also suitable for the assessment of nanotechnology-enabled health products. 
Qualification and validation of in silico methods 
Physiologically-based pharmacokinetic (PBPK) modelling is now routinely utilised to aid an efficient and quantitative 
understanding of the pharmacokinetic-pharmacodynamic relationship of small-molecule drugs and their metabolites. The tool 
has been increasingly recognised by regulatory bodies in recent years to facilitate drug development programs. In terms of 
nanomedicine development, the application of PBPK models for the informed simulation of first-in-human studies, drug-drug 
interactions, formulation changes and extrapolation to special populations can provide a substantial insight into the 
pharmacological behaviour of a nanomedicine compared to conventional drug. Although there are no specific guidelines on 
the use of PBPK in nanomedicine development, there is some guidance on the general use of PBPK analyses to support 
applications to regulatory bodies (Table B.5). 
Table B.5: Guidance documents related to PBPK modelling. 
The EMA have drafted a guidance document describing the qualification and reporting of PBPK modelling and simulation 
approaches suitable for clinical development decision making (Table B.5). This document details the qualification of platforms 
suitable for PBPK and what is required in terms of model validation. For the general qualification of a PBPK platform i.e. a 
version of PBPK software for an intended purpose, this may be reviewed via a CHMP qualification procedure following the 
Qualification of novel methodologies for drug development guidelines (EMA/CHMP, 2014) (see section above). The predictive 
performance of the platform should then be further evaluated if it is to be used for an intended purpose (EMA/CHMP, 2018). 
This process should involve a detailed description of the model parameters, the equations used, how preliminary data was 
derived (if experimental) and a discussion on the source of any data collected from the literature. The requirements for 
qualification depend on the impending regulatory impact that data provided by the model may have if clinical decisions were 
to be made on its basis. This can be classified as high, moderate or low. The guidance recommends information should be 
provided on aspects of model structure, model performance in terms of sensitivity and level of confidence, and the final 
model results that should include a discussion of the simulation results and their regulatory consequences. There are a 
number of issues raised by academic and industry reviewers that mainly concern an uncertainty surrounding the qualification 
process where the regulators are advised to provide more detail in their requirements. For example, can a model be qualified 
to predict a pharmacokinetic parameter in general or does each model need to be drug-specific? These issues may be 
addressed before the final versions of the guidance are prepared. 
The FDA also provides final guidance on the recommended format and content for the submission of PBPK analyses to 
support various applications (Table B.5). A report should provide a comprehensive overview of what is known of the drug 
being investigated already and references to any PBPK analyses that have been performed previously, as well as a workflow 
Agency Document Scope 
EMA/CHMP 
Qualification and reporting of physiologically based 
pharmacokinetic (PBPK) modelling and simulation. 
EMA/CHMP/458101/2016(EMA/CHMP, 2018) 
 Content of modelling and simulation reports 
 Qualification of PBPK platforms 
FDA/CDER 
Guidance for Industry: Physiologically Based 
Pharmacokinetic Analyses — 
Format and Content (Sep. 2018)(FDA, 2016) 
 Structure and content of PBPK study reports 
 Does not address methodologies or best practices 
Commented [HKB(13]: Key reference reg acceptance 3R 
can a model be qualified to predict a pharmacokinetic parameter in general or does each model need 
to be drug-specific? These issues may be a dressed bef re th  final versions f the guidance are 
prepared.
The FDA also provides final guidance on the recommended format and content for the submission of 
PBPK analyses to support various applications (Table B.5). A report should provide a comprehensive 
overview of what is known of the drug being investigated already and references to any PBPK analyses 
that have been performed previously, as well as a workflow for the construction and implementation 
of the model. This should include sufficient detail so that reviewers are able to duplicate the model to 
evaluate the integrity of the presented data. The methodology should also include the software used, 
but the FDA does not recommend the use of any specific software for PBPK modelling. Results should 
include data surrounding the model verification and any modifications that were made in order to 
demonstrate the model is appropriate for its application. The final application results should then be 
presented and discussed to address the original study question. 
 FDA procedure for medical devices methods
The Medical Device Development Tools (MDDT) program is an FDA’s program for the qualification 
of tools that can be used in the development and evaluation of a medical device17. It applies to a 
method, material or measurement, which assesses the safety, efficacy or performance of a medical 
device. When a method after approval via the MDDT procedure, is used in a regulatory submission, the 
reviewers should accept the methodology without the need to reconfirm its suitability and utility. This 
can speed up and facilitate the development and evaluation of a new medical device which reduces 
costs and time and therefore makes new medical devices quicker available for the patient. The FDA 
recognizes 3 categories of MDDT based on how the parameters are measured: Clinical Outcome 
Assessments (which measure how a patient feels or functions), Biomarker tests (a laboratory test or 
instrument that detects or measures biomarkers) and Non Clinical assessment Models (a nonclinical 
test method or model that measures or predicts device function or performance in a living organism). 
The qualification process consist of several phases and starts with the proposal phase in which the 
FDA determines if the MDDT is suitable for qualification in the MDDT program. The proposals that 
have the strongest potential to meet a public health need will be prioritised. This phase might be 
followed by the incubator phase. In certain instances an MDDT with a high potential impact may 
be accepted while the MDDT is not fully developed.  During the incubator phase, the FDA will foster 
the development of the tool. Also the pre-qualification phase in which the FDA provides feedback to 
the submitters is optional. The goal of the qualification phase is to determine whether the MDDT is 
qualified for the specific context based on scientific evidence and the provided justification. The FDA 
has released the first two MDDTs namely the Kansas City Cardiomyopathy Questionnaire (KCCQ) 
which qualifies patient health status and the Minnesota Living with Hearth Failure Questionnaire 
(MLHFQ) which measures quality of life for hearth failure patients. 
17MDDT program: https://www.fda.gov/medicaldevices/
scienceandresearch/medicaldevicedevelopmenttools-
mddt/
Table B.5: Guidance documents related to PBPK modelling
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ANNEX C. Overview of products 
on the market 
The number of nanotechnology-enabled health products that have reached the European market is 
constantly increasing. They can be regulated either as medicinal products or medical devices. Most 
widely used nanotechnological platforms and applications are described below.
C.1 Nanotechnology-enabled medicinal 
products 
Most of the currently approved nanotechnology-enabled medicinal products are based on conventional 
active substances that had already been approved. The employed platforms may contain a 
nanoparticle (such as liposome or polymer) with a bound or encapsulated active substance or may be 
formed directly from the constituent drug in a nano-form. The remainder of investigational products 
demonstrate a trend toward agents using micelles, as well as the introduction of formulations using 
dendrimers (Caster, Patel, Zhang, & Wang, 2017; Robinson, Corrie, Thurecht, Islam, & Bobo, 2016). 
Among the approved products on the market (Figure C.1 and Table C.1) (Hafner, Lovrić, Lakǒ, & Pepić, 
2014; Patra et al., 2018; Pita et al., 2016) the main nanotechnology platforms include:
1) Nanocrystals, consisting of pure active substance in form of particles in a nano-size. They 
offer better solubility and bioavailability of the drug;
2) Polymer-protein conjugates: the conjugation of protein with a polymer such as poly(ethylene 
glycol) (PEG) leads to a longer circulation in bloodstream and can be designed to influence the 
biological activity;
3) Amino-acid based polymers, biodegradable polymers allowing tailored functionalization and 
controlled drug delivery;
4) Nano-emulsions: dispersion systems consisting of oil, surfactants, co-surfactants, and 
aqueous phase, where the active substance is distributed in the lipid droplets of a nano-size;
5) Liposomes: vesicles encapsulating active substance in one or more lipid bilayers, protecting 
active substance from being metabolized early and delivering it to the site of disease;
6) Iron–carbohydrate complexes in a colloidal suspension, used in iron deficiency disorders. They 
provide high doses of iron in a stable, non-toxic form with a reduced risk of hypersensitivity 
reactions.
7) Virosomes, which consist of virus-derived proteins encapsulated in unilamellar phospholipid 
membrane which allows the virosomes to fuse with target cells. They act as a vaccine carriers 
and adjuvants (immunity enhancing) systems, combining high efficacy with the improved safety.
Figure C.1: Illustration of the diversity of nanotechnology-enabled medicinal products
In all cases the main advantages are related to the improved pharmacokinetic (PK) properties such as:
• Prolonged stability and blood circulation
• Improved transport across biological barriers
• Preferential distribution within the body
• Controlled and site specific release
• Improved solubility of hydrophobic drugs
Thanks to these properties the efficacy of a medicine is increased allowing the reduction of dosage 
and limiting the risk of side effects. 
The anticancer and antimicrobial therapeutics are the most numerous categories among the approved 
and investigational products (Noorlander et al., 2015). But there are formulations being developed 
NANOMEDICINES
POLYMER-PROTEIN CONJUGATES
AMINO-ACID BASED POLYMERS
LIPOSOMES
VIROSOMES
IRON–CARBOHYDRATE COMPLEXES
NANO-EMULSIONS
NANOCRYSTALS
for autoimmune conditions, anaesthesia, metabolic disorders, ophthalmic conditions, neurological and 
psychiatric diseases, and others (Caster et al., 2017).
C.2 Nanotechnology-enabled medical devices
Nanotechnology applications in the field of medical devices span a wide range of extremely diverse 
products, technologies and application areas (Figure C.2) (Geertsma et al., 2015). 
They are used for therapy, diagnosis, monitoring and prevention of diseases. Many different medical 
disciplines benefit from nanomedical devices.
Nanomaterials are used in coatings of various implants (Table C.2). Examples are coatings on stents 
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(cardiology), dental implants (dentistry) and hip implants (orthopedics). Coatings are used on these 
implants for various reasons. Nanocoatings can improve the biocompatibility and haemocompatbility 
by masking the surface of the implant to prevent pathological reactions. Nanomaterials in the coating 
can also improve the interaction between the implant surface and the surrounding bone or tissue, 
decreasing the risk that the implant loosens. Applying coatings to blood contacting surfaces reduces 
the risk of thrombosis. In addition, some nanomaterials like silver nanoparticles have antimicrobial 
properties preventing infections around the implant. Coatings may also form a barrier preventing the 
migration of heavy metal ions, which might provoke an allergic reaction. There are also nanocoatings 
that swell in time which induces a controlled drug release. In implantable pacing leads (cardiology) 
nanocoatings optimize the electrically active surface area.
Figure C.2: Most spread nanotechnology applications in medical devices
Nanomaterials can also mimic natural tissues. With help of nanotechnology, optimal biological, 
physical and mechanical properties can be realized. In orthopaedics, nanomaterials are used as a 
matrix for bone regeneration. This matrix favours cell adhesion, stimulates bone growth and gives 
mechanical strength. Nanomaterials are also used in skin substitutes since these materials mimic 
the natural extracellular matrix to provide a microenvironment for wound healing and cell growth. 
In dentistry, nanomaterials are used in dental and root canal fillers to improve the physical and 
mechanical properties.
Nanotechnology has specific applications in oncology. Examples are diagnostic tests in which 
nanoparticles coated with an antibody detect cancer in an early stage or determine tumour boundaries 
or metastasis during surgical procedures. Nanomaterials can also increase the effect of chemotherapy 
NANOMEDICAL
DEVICES
SCAFFOLDS
ANTIMICROBIAL MEMBRANES
RADIOSENSITIZER
HYPERTHERMIA
DENTAL MATERIAL
VASCULAR GRAFTS
BIOSENSORS AND
DIAGNOSTICS
SKIN-TISSUE REPAIR
MEDICAL IMPLANTS
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Nanotechnology 
platform 
Advantage of 
nanotechnological 
approach 
Active substance Commercial name Indication(s) 
Nanocrystal Increased dissolution velocity 
resulting in improved 
bioavailability 
Fenofibrate/simvastatin Cholib® Dyslipidaemias 
Fenofibrate 
Tricor® Lipanthyl® 
Lipidil® 
Hyperlipidaemia 
Sirolimus Rapamune® 
Prophylaxis of organ rejection in renal 
transplant 
Aprepitant Emend® Nausea and vomiting 
Paliperidone palmitate Xeplion® Schizophrenia 
Olanzapine pamoate Zypadhera® Schizophrenia 
Liposome 
Drug delivery system, 
increased accumulation of the 
drug at the site of disease, 
protection of the drug from 
being metabolised too early, 
reduction of side effects 
Doxorubicin hydrochloride 
Caelyx®
Myocet® 
Breast neoplasms,/ Multiple myeloma / 
Ovarian neoplasms / Kaposi’s sarcoma 
Metastatic breast cancer 
Irinotecan Onivyde® Metastatic adenocarcinoma of the pancreas 
Amphotericin B AmBisome® Fungal infection 
Daunorubicin DaunoXome® Advanced HIV-related Kaposi’s Sarcoma 
Hepatitis A vaccine Epaxal® Active immunisation against hepatitis A 
Cytarabine DepoCyte® Lymphomatous meningitis 
Mifamurtide Mepact® Osteosarcoma 
Propofol 
privan®/Propofol 
Lipuro®/Propofol® 
Anaesthesia 
Verteporfin Visudyne® 
Degenerative myopia /age-related macular 
degeneration 
Morphine DepoDur® Pain 
Albumin-bound 
drug nanoparticle 
Increased site-specific delivery 
and solubility Nab-paclitaxel Abraxane® 
Breast neoplasms /Carcinoma non-small-
cell lung /Pancreatic neoplasm 
Mixture of synthetic 
polypeptides Glatiramer acetate Copaxone®, Synthon® Multiple sclerosis 
Polymeric amine 
Increased circulation and 
therapeutic delivery Sevelamer Renagel®/Renvela® Dialysis/ hyperphosphatemia 
Table C.1 Examples of nanotechnology-enabled medicinal products currently on the European market (non-exhaustive)
During surgery, suture needles and surgical blades can be used which are manufactured with 
nanomaterials. These nanomaterials make the surgical equipment stronger, lighter and extremely 
sharp which reduces tissue damage. Surgical gloves can be made of antibacterial textile containing 
nanomaterials.
Key reference:
Geertsma et al (2015). Nanotechnologies in medical 
devices. RIVM Rep. 2015-0149.
and radiation by increasing the temperature locally (hyperthermia) or direct killing of local tumour 
cells (ablation). 
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Nanotechnology 
platform 
Advantage of 
nanotechnological 
approach 
Active substance Commercial name Indication(s) 
Monoclonal 
antibody 
conjugated to 
radioactive isotope 
Yttrium-90 radiolabelled 
ibritumomab tiuxetan 
Zevalin® Follicular Lymphoma 
Polymer-protein 
conjugates 
Improved pharmacokinetic 
properties, prolonged stability 
Pegaspargase 
(mPEGasparaginase) 
Oncaspar® Acute lymphocytic leukaemia 
Peginterferon alpha-2b PegIntron® Chronic hepatitis C 
Peginterferon alpha-2a Pegasys® Chronic hepatitis B and C 
Pegfilgastrim Neulasta® Leukopenia by chemotherapy 
Methoxy polyethylene 
glycol-epoetin beta 
Mircera® 
Anaemia associated with chronic kidney 
disease 
Certolizumab pegol CimziaTM Rheumatoid arthritis 
Pegvisomant  (PEGHGH 
antagonist) 
Somavert® Acromegaly 
Nano-emulsion 
Encapsulation and delivery of 
hydrophobic drugs, 
Improvement of 
pharmacokinetic properties 
Ritonavir Norvir® HIV infection, 
Cyclosporine Neoral® 
Prophylaxis of organ rejection after 
transplantation 
Cyclosporine Sandimmun Neoral® 
Solid organ, bone marrow transplantation 
Endogenous uveitis 
Nephrotic syndrome 
Rheumatoid arthritis, Psoriasis 
Atopic dermatitis 
Iron–carbohydrate 
complexes 
Improved dose capacity 
improved tolerance 
Ferumoxytol Rienso® 
Iron deficiency, anaemia in adult patients 
with chronic kidney disease 
Ferric carboxymaltose Ferinject® Iron deficiency 
Iron sucrose [iron(III)-
hydroxidesucrose 
complex] 
Visudyne® Iron deficiency 
Iron(III) isomaltoside Monofer® Iron deficiency 
Iron(III)-hydroxide dextran 
complex 
Ferrisat®/Cosmofer® Iron deficiency 
Virosome 
High efficacy in enhancing 
immune response and 
improved safety 
Adjuvanted influenza 
vaccine 
Inflexal® V Vaccine against influenza 
Inactivated hepatitis A virus Epaxal® Vaccine against hepatitis A 
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Nanotechnology 
platform 
Advantage of 
nanotechnological 
approach 
Active substance Commercial name Indication(s) 
Gas  dispersion in 
form of 
"microbubbles" 
Enhances performance of the 
imaging technique 
Sulphur hexafluoride 
SonoVue®sulphur 
hexafluoride 
Contrast agent for echocardiography and 
ultrasonography 
Table C.2: Examples of nanotechnology-based medical devices currently on the market (Geertsma et al., 2015). 
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Product Discipline Application nanoparticle Advantages Example of product 
Stents (bare metal 
and drug eluting 
stents) 
Cardiology Coating: improve biocompatibility and haemocompatibility 
Due to hydrophobicity and 
smooth surface. Create barrier 
for migrating heavy metal ions. 
Mask stent surface which 
prevents pathological 
reactions. To trap drugs and 
release it slowly. 
MOMO® 
Cre8TM 
(drug coated) Balloons Cardiology Coating: controlled release of drug 
during swelling 
DIOR® 
Ventricular assist 
device 
Cardiology Coating blood contacting surface: 
minimize thrombosis 
VentrAssisstTM 
Implantable pacing 
lead 
Cardiology Coating: optimize electrically active 
surface area 
(Biotronik SE&Co 
KG) 
Pacemaker Cardiology 
Magnetoresistive sensor: more 
sensitive sensor to communicate and 
receive instructions faster 
(St Jude Medical, 
Inc) 
Dental composite Dentistry 
Dental filler: improve mechanical 
properties 
Aesthetic properties, reduce 
working and setting times of 
resins 
Ceram-X® 
Dental implants Dentistry Coating: improve biocompatibility Increase cell adhesion 
Bonding agent Dentistry 
Ensure product homogeneity and 
better mixing 
Dental material Dentistry 
Antimicrobial properties to prevent 
secondary caries 
Impression material Dentistry 
Filler: provide tear, distortion and heat 
resistance 
Root canal sealer/filler Dentistry Antimicrobial properties, better fit, improved physical properties 
Veneering material 
(tooth coating) 
Dentistry Prevent discoloration, increase wear 
resistance 
Diagnostics a.o. Oncology Nanoparticles coated with antibodies 
bind to biomarkers 
Immobilization device Oncology High strength and thinner material 
Hyperthermia/ablative 
devices 
Oncology 
Nanoparticles generate heat when 
exposed to alternating magnetic field. 
Inducing hyperthermia or ablation. 
NanoTherm® 
Tumour tracer Oncology 
Tumour localization by accumulate in 
lymph node and detection by the 
magnetic properties 
Sienna+® 
Table C.2 Examples of nanotechnology-based medical devices currently on the market (Geertsma et al., 2015)
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Orthopaedic implants 
(artificial knee, hip) Orthopaedics Coating: improve biocompatibility 
Improve interaction between 
implant surface and 
surrounding bone or soft 
tissue. 
Bone filler/bone graft Orthopaedics Matrix for bone regeneration. 
Favour cell adhesion and 
stimulate new bone growth. 
Adjustable degradation time 
and mechanical strength 
Suture needles Surgery 
Lighter, high strength and good 
ductility which reduces tissue damage 
Surgical blades Surgery 
Coating:  extreme sharpness, low 
friction and low adhesion 
Sealing vessels Surgery 
Electrode consists of nanometer sized 
conductive particles for heat 
regulation 
Wound dressings Wound 
care/healing 
Antibacterial and antifungal (silver 
nanoparticles) 
Mechanical support, tensile 
strength, stiffness, flexibility. 
Promote haemostasis thanks 
to Smaller pore size , larger 
surface area 
Skin substitutes Wound 
care/healing 
Mimic natural extracellular matrix to 
provide microenvironment for wound 
healing and cell growth 
Medical textiles All disciplines 
Antibacterial textile products such as 
patient dresses, bed lines, reusable 
surgical gloves 
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